-
1
-
-
0023663885
-
Functional domains of the human estrogen receptor
-
Kumar V, Green S, Stack G, Berry M, Jin J-R, Chambon P: Functional domains of the human estrogen receptor. Cell 51: 941-951, 1987
-
(1987)
Cell
, vol.51
, pp. 941-951
-
-
Kumar, V.1
Green, S.2
Stack, G.3
Berry, M.4
Jin, J.-R.5
Chambon, P.6
-
2
-
-
0030667676
-
Molecular basis of agonism and antagonism in the oestrogen receptor
-
Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389: 753-758, 1997
-
(1997)
Nature
, vol.389
, pp. 753-758
-
-
Brzozowski, A.M.1
Pike, A.C.W.2
Dauter, Z.3
Hubbard, R.E.4
Bonn, T.5
Engstrom, O.6
Ohman, L.7
Greene, G.L.8
Gustafsson, J.A.9
Carlquist, M.10
-
3
-
-
0024317270
-
The human estrogen receptor has two independent nonacidic transcriptional activation functions
-
Tora L, White J, Brou C, Tassett D, Webster N, Scheer E, Chambon P: The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59: 477-487, 1989
-
(1989)
Cell
, vol.59
, pp. 477-487
-
-
Tora, L.1
White, J.2
Brou, C.3
Tassett, D.4
Webster, N.5
Scheer, E.6
Chambon, P.7
-
4
-
-
84995870933
-
Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intranolecular regions
-
Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP: Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intranolecular regions. Mot Endocrinol 8: 21-30, 1994
-
(1994)
Mot Endocrinol
, vol.8
, pp. 21-30
-
-
Tzukerman, M.T.1
Esty, A.2
Santiso-Mere, D.3
Danielian, P.4
Parker, M.G.5
Stein, R.B.6
Pike, J.W.7
McDonnell, D.P.8
-
5
-
-
0023712331
-
The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function
-
Webster NJG, Green S, Jin JR, Chambon P: The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell 54: 199-207, 1988
-
(1988)
Cell
, vol.54
, pp. 199-207
-
-
Webster, N.J.G.1
Green, S.2
Jin, J.R.3
Chambon, P.4
-
6
-
-
0025062215
-
Role of the two activating domains of the estrogen receptor in the cell-type and promoter-context dependent agonist activity of the antiestrogen 4-hydroxytamoxifen
-
Berry M, Metzger D, Chambon P: Role of the two activating domains of the estrogen receptor in the cell-type and promoter-context dependent agonist activity of the antiestrogen 4-hydroxytamoxifen. EMBO J 9: 2811-2818, 1990
-
(1990)
EMBO J
, vol.9
, pp. 2811-2818
-
-
Berry, M.1
Metzger, D.2
Chambon, P.3
-
7
-
-
0024343546
-
The transcriptional activation function located in the hormone binding domain of the human estrogen receptor is not encoded in a single exon
-
Webster NJG, Green S, Tasset D, Panglikitmongkol M Chambon P: The transcriptional activation function located in the hormone binding domain of the human estrogen receptor is not encoded in a single exon. EMBO J 8: 1441-1446, 1989
-
(1989)
EMBO J
, vol.8
, pp. 1441-1446
-
-
Webster, N.J.G.1
Green, S.2
Tasset, D.3
Panglikitmongkol, M.4
Chambon, P.5
-
8
-
-
0030910962
-
Identification of a third autonomous activation domain within the human estrogen receptor
-
Norris JD, Fan DJ, Kerner SA, McDonnell DP: Identification of a third autonomous activation domain within the human estrogen receptor. Mol Endocrinol 11: 747-754, 1997
-
(1997)
Mol Endocrinol
, vol.11
, pp. 747-754
-
-
Norris, J.D.1
Fan, D.J.2
Kerner, S.A.3
McDonnell, D.P.4
-
9
-
-
0030579801
-
Cloning of a novel estrogen receptor expressed in rat prostate and ovary
-
Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J: Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93: 5925-5930, 1996
-
(1996)
Proc Natl Acad Sci USA
, vol.93
, pp. 5925-5930
-
-
Ggjm, K.1
Enmark, E.2
Pelto-Huikko, M.3
Nilsson, S.4
Gustafsson, J.5
-
10
-
-
0030995199
-
The estrogen receptor activity cycle: Dependence on multiple protein-protein interactions
-
Lieberman BA: The estrogen receptor activity cycle: dependence on multiple protein-protein interactions. Crit Rev Eukaryotic Gene Expression 7: 43-59, 1997
-
(1997)
Crit Rev Eukaryotic Gene Expression
, vol.7
, pp. 43-59
-
-
Lieberman, B.A.1
-
11
-
-
0031932603
-
Cross-talk between peptide growth factor and estrogen receptor signaling pathways
-
Smith CL: Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol Reprod 58: 627-632, 1998
-
(1998)
Biol Reprod
, vol.58
, pp. 627-632
-
-
Smith, C.L.1
-
12
-
-
0028886694
-
Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
-
Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491-1496, 1995
-
(1995)
Science
, vol.270
, pp. 1491-1496
-
-
Kato, S.1
Endoh, H.2
Masuhiro, Y.3
Kitamoto, T.4
Uchiyama, S.5
Sasaki, H.6
Masushige, S.7
Gotoh, Y.8
Nishida, E.9
Kawashima, H.10
Metzger, D.11
Chambon, P.12
-
13
-
-
0032436976
-
Molecular mechanism of a cross-talk between estrogen and growth-factor signaling pathways
-
Kato S, Kitamoto T, Masuhiro Y, Yanagisawa J: Molecular mechanism of a cross-talk between estrogen and growth-factor signaling pathways. Oncology 55: 5-10, 1998
-
(1998)
Oncology
, vol.55
, pp. 5-10
-
-
Kato, S.1
Kitamoto, T.2
Masuhiro, Y.3
Yanagisawa, J.4
-
14
-
-
0032557452
-
Estradiol-induced phosphorylation of serine 118 is in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase
-
Joel PB, Traish AM, Lannigans DA: Estradiol-induced phosphorylation of serine 118 is in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. J Biol Chem 273: 13317-13323, 1998
-
(1998)
J Biol Chem
, vol.273
, pp. 13317-13323
-
-
Joel, P.B.1
Traish, A.M.2
Lannigans, D.A.3
-
15
-
-
0030931670
-
Regulation of estrogen receptor transcriptional enhancement by the cyclinA/Cdk2 complex
-
Trowbridge JM, Rogatsky I, Garabedian MJ: Regulation of estrogen receptor transcriptional enhancement by the cyclinA/Cdk2 complex. Proc Natl Acad Sci USA 94: 10132-10137, 1997
-
(1997)
Proc Natl Acad Sci USA
, vol.94
, pp. 10132-10137
-
-
Trowbridge, J.M.1
Rogatsky, I.2
Garabedian, M.J.3
-
16
-
-
0025329841
-
Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor
-
Fawell SE, Lees JA White R, Parker MG: Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor. Cell 60: 953-962, 1990
-
(1990)
Cell
, vol.60
, pp. 953-962
-
-
Fawell, S.E.1
Lees, J.A.2
White, R.3
Parker, M.G.4
-
17
-
-
0023034983
-
An estrogen responsive element derived from the 5′ flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells
-
Klein-Hitpass L, Schorpp M, Wagner U, Ryffel CU: An estrogen responsive element derived from the 5′ flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells. Cell 46: 1053-1061, 1986
-
(1986)
Cell
, vol.46
, pp. 1053-1061
-
-
Klein-Hitpass, L.1
Schorpp, M.2
Wagner, U.3
Ryffel, C.U.4
-
18
-
-
0023808861
-
The estrogen receptor binds tightly to its response element as a ligand-induced homodimer
-
Kumar V, Chambon P: The estrogen receptor binds tightly to its response element as a ligand-induced homodimer. Cell 55: 145-156, 1988
-
(1988)
Cell
, vol.55
, pp. 145-156
-
-
Kumar, V.1
Chambon, P.2
-
19
-
-
0027235507
-
High affinity binding of the estrogen receptor to a DNA response element does not require homodimer formation or estrogen
-
Furlow JD, Murdoch FE, Gorski J: High affinity binding of the estrogen receptor to a DNA response element does not require homodimer formation or estrogen. J Biol Chem 268: 12519-12525, 1993
-
(1993)
J Biol Chem
, vol.268
, pp. 12519-12525
-
-
Furlow, J.D.1
Murdoch, F.E.2
Gorski, J.3
-
20
-
-
0030451142
-
Interaction of steroid hormone receptors with the transcription initiation complex
-
Beato M, Sanchez-Pacheco A: Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev 17: 587-609, 1996
-
(1996)
Endocr Rev
, vol.17
, pp. 587-609
-
-
Beato, M.1
Sanchez-Pacheco, A.2
-
22
-
-
0028113345
-
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
-
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo Y, Gholami Z, Shaffer D, Bayer S, Wray C, Bogden R, Dayanath P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Wiseman R, Kamb A, Skolnick MH: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71, 1994
-
(1994)
Science
, vol.266
, pp. 66-71
-
-
Miki, Y.1
Swensen, J.2
Shattuck-Eidens, D.3
Futreal, P.A.4
Harshman, K.5
Tavtigian, S.6
Liu, Q.7
Cochran, C.8
Bennett, L.M.9
Ding, W.10
Bell, R.11
Rosenthal, J.12
Hussey, C.13
Tran, T.14
McClure, M.15
Frye, C.16
Hattier, T.17
Phelps, R.18
Haugen-Strano, A.19
Katcher, H.20
Yakumo, Y.21
Gholami, Z.22
Shaffer, D.23
Bayer, S.24
Wray, C.25
Bogden, R.26
Dayanath, P.27
Ward, J.28
Tonin, P.29
Narod, S.30
Bristow, P.K.31
Norris, F.H.32
Helvering, L.33
Morrison, P.34
Rosteck, P.35
Lai, M.36
Barrett, J.C.37
Lewis, C.38
Neuhausen, S.39
Cannon-Albright, L.40
Wiseman, R.41
Kamb, A.42
Skolnick, M.H.43
more..
-
23
-
-
0033591295
-
BRCAI inhibition of estrogen receptor signaling in transfected cells
-
Fan S, Wang J-A, Yuan R, Ma Y, Meng Q, Erdos MR, Pestell RG, Yuan F, Auborn KJ, Goldberg ID, Rosen EM: BRCAI inhibition of estrogen receptor signaling in transfected cells. Science 284: 1354-1356, 1999
-
(1999)
Science
, vol.284
, pp. 1354-1356
-
-
Fan, S.1
Wang, J.-A.2
Yuan, R.3
Ma, Y.4
Meng, Q.5
Erdos, M.R.6
Pestell, R.G.7
Yuan, F.8
Auborn, K.J.9
Goldberg, I.D.10
Rosen, E.M.11
-
24
-
-
0029841146
-
Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene
-
Yang NN, Venugopalan M, Hardikar S, Glasebrook A: Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 273: 1222-1225, 1996
-
(1996)
Science
, vol.273
, pp. 1222-1225
-
-
Yang, N.N.1
Venugopalan, M.2
Hardikar, S.3
Glasebrook, A.4
-
25
-
-
0027205024
-
Estradiol increases and antiestrogens antagonize the growth factor-induced activator protein-1 activity in MCF-7 breast cancer cells without affecting c-fos or c-jun synthesis
-
Philips A, Chalbos D, Rochefort H: Estradiol increases and antiestrogens antagonize the growth factor-induced activator protein-1 activity in MCF-7 breast cancer cells without affecting c-fos or c-jun synthesis. J Biol Chem 268: 14103-14108, 1993
-
(1993)
J Biol Chem
, vol.268
, pp. 14103-14108
-
-
Philips, A.1
Chalbos, D.2
Rochefort, H.3
-
26
-
-
0032479304
-
Steroid receptor coactivator-1 coactivates activating protein-1-mediated transactivations through interaction with the c-Jun and c-Fos subunits
-
Lee SK, Kim HJ, Na SY, Kim TS, Choi HS, Im SY, Lee JW: Steroid receptor coactivator-1 coactivates activating protein-1-mediated transactivations through interaction with the c-Jun and c-Fos subunits. J Biol Chem 273: 16651-16654, 1998
-
(1998)
J Biol Chem
, vol.273
, pp. 16651-16654
-
-
Lee, S.K.1
Kim, H.J.2
Na, S.Y.3
Kim, T.S.4
Choi, H.S.5
Im, S.Y.6
Lee, J.W.7
-
27
-
-
0025817801
-
Dopaminergic and ligand-independent activation of steroid hormone receptors
-
Power RF, Lydon JP, Conneely OM, O'Malley BW: Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 252: 1546-1547, 1991
-
(1991)
Science
, vol.252
, pp. 1546-1547
-
-
Power, R.F.1
Lydon, J.P.2
Conneely, O.M.3
O'Malley, B.W.4
-
28
-
-
0030888284
-
Estrogen-induced activation of CDK4 and CDK2 during G1>S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-CDK2
-
Prall OWJ, Sarcevic B, Musgrove EA, Watts CKW, Sutherland RL: Estrogen-induced activation of CDK4 and CDK2 during G(1>S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-CDK2. J Biol Chem 272: 10882-10894, 1997
-
(1997)
J Biol Chem
, vol.272
, pp. 10882-10894
-
-
Prall, O.W.J.1
Sarcevic, B.2
Musgrove, E.A.3
Watts, C.K.W.4
Sutherland, R.L.5
-
29
-
-
0027956282
-
Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cells
-
Watts CKW, Sweeney KJE, Walters A, Musgrove EA, Sutherland RL: Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cells. Breast Cancer Res Treat 31: 95-105, 1994
-
(1994)
Breast Cancer Res Treat
, vol.31
, pp. 95-105
-
-
Watts, C.K.W.1
Sweeney, K.J.E.2
Walters, A.3
Musgrove, E.A.4
Sutherland, R.L.5
-
30
-
-
0028786916
-
Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation
-
Watts CKW, Brady A, Sarcevic B, DeFazio A, Musgrove EA, Sutherland RL: Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol 9: 1804-1813, 1995
-
(1995)
Mol Endocrinol
, vol.9
, pp. 1804-1813
-
-
Watts, C.K.W.1
Brady, A.2
Sarcevic, B.3
DeFazio, A.4
Musgrove, E.A.5
Sutherland, R.L.6
-
31
-
-
0030927929
-
Esaogen-dependent cyclin E-CDK2 activation through p21 redistribution
-
Planassilo MD, Weinberg RA: Esaogen-dependent cyclin E-CDK2 activation through p21 redistribution. Mol Cell Biol 17: 4039-4069, 1997
-
(1997)
Mol Cell Biol
, vol.17
, pp. 4039-4069
-
-
Planassilo, M.D.1
Weinberg, R.A.2
-
32
-
-
0343618126
-
Mechanisms of antiestrogen, progestin/antiprogestin, and retinoid inhibition of cell cycle progression in breast cancer cells
-
Pasqualini JR, Katzenellenbogen BS (eds) Marcel Dekker, New York
-
Watts CKW, Wilcken NRC, Hamilton JA, Sweeney KJE, Musgrove EA, Sutherland RL: Mechanisms of antiestrogen, progestin/antiprogestin, and retinoid inhibition of cell cycle progression in breast cancer cells. In: Pasqualini JR, Katzenellenbogen BS (eds) Hormone Dependent Cancer. Marcel Dekker, New York, 1996, pp 119-140
-
(1996)
Hormone Dependent Cancer
, pp. 119-140
-
-
Watts, C.K.W.1
Wilcken, N.R.C.2
Hamilton, J.A.3
Sweeney, K.J.E.4
Musgrove, E.A.5
Sutherland, R.L.6
-
33
-
-
0028875555
-
Hormone-dependent regulation of BRCAI in human breast cancer cells
-
Gudas JM, Nguyen H, Li T, Cowan KH: Hormone-dependent regulation of BRCAI in human breast cancer cells. Cancer Res 55: 4561-4565, 1995
-
(1995)
Cancer Res
, vol.55
, pp. 4561-4565
-
-
Gudas, J.M.1
Nguyen, H.2
Li, T.3
Cowan, K.H.4
-
34
-
-
0031026002
-
BRCA1 expression is not directly responsive to estrogen
-
Marks JR, Huper G, Vaughn JP, Davis PL, Norris J, McDonnell DP, Wiseman RW, Futreal PA, Iglehart JD: BRCA1 expression is not directly responsive to estrogen. Oncogene 14: 115-121, 1997
-
(1997)
Oncogene
, vol.14
, pp. 115-121
-
-
Marks, J.R.1
Huper, G.2
Vaughn, J.P.3
Davis, P.L.4
Norris, J.5
McDonnell, D.P.6
Wiseman, R.W.7
Futreal, P.A.8
Iglehart, J.D.9
-
35
-
-
0031605753
-
Interactions between the oestrogen and insulin-like growth factor signalling pathways in the control of breast epithelial cell proliferation
-
Westley BR, Clayton SJ, Daws MR, Molloy CA, May FEB: Interactions between the oestrogen and insulin-like growth factor signalling pathways in the control of breast epithelial cell proliferation. Biochem Soc Symp 63: 35-44, 1998
-
(1998)
Biochem Soc Symp
, vol.63
, pp. 35-44
-
-
Westley, B.R.1
Clayton, S.J.2
Daws, M.R.3
Molloy, C.A.4
Feb, M.5
-
36
-
-
0026037159
-
Oestrogen directly stimulates growth factor signal tranaduction pathways in human breast cancer cells
-
Van der Burg B, De Groot RP, Isbrücker L, Kruijer W, De Laat SW: Oestrogen directly stimulates growth factor signal tranaduction pathways in human breast cancer cells. J Steroid Biochem Mol Biol 40: 215-221, 1991
-
(1991)
J Steroid Biochem Mol Biol
, vol.40
, pp. 215-221
-
-
Van Der Burg, B.1
De Groot, R.P.2
Isbrücker, L.3
Kruijer, W.4
De Laat, S.W.5
-
37
-
-
0029821812
-
Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients
-
Helle SI, Holly JMP, Tally M, Hall K, Van der Stappen J, Lonning PE: Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int J Cancer 69: 335-339, 1996
-
(1996)
Int J Cancer
, vol.69
, pp. 335-339
-
-
Helle, S.I.1
Jmp, H.2
Tally, M.3
Hall, K.4
Van Der Stappen, J.5
Lonning, P.E.6
-
38
-
-
0026600841
-
Identification of a conserved region required for hormone-dependent transcriptional activation by steroid hormone receptors
-
Danielian PS, White R, Lees JA, Parker MG: Identification of a conserved region required for hormone-dependent transcriptional activation by steroid hormone receptors. EMBO J 11: 1025-1033, 1992
-
(1992)
EMBO J
, vol.11
, pp. 1025-1033
-
-
Danielian, P.S.1
White, R.2
Lees, J.A.3
Parker, M.G.4
-
39
-
-
0345567604
-
Molecular determinants of tissue selectivity in estrogen receptor modulators
-
Grese TA, Sluka JP, Bryant HU, Cullinan GJ, Glasebrook AL, Jones CD, Matsumoto K, Palkowitz AD, Sato M, Termine JD, Winter MA, Yang NN, Dodge JA: Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci USA 94: 14105-14110, 1997
-
(1997)
Proc Natl Acad Sci USA
, vol.94
, pp. 14105-14110
-
-
Grese, T.A.1
Sluka, J.P.2
Bryant, H.U.3
Cullinan, G.J.4
Glasebrook, A.L.5
Jones, C.D.6
Matsumoto, K.7
Palkowitz, A.D.8
Sato, M.9
Termine, J.D.10
Winter, M.A.11
Yang, N.N.12
Dodge, J.A.13
-
40
-
-
0029978077
-
Human estrogen receptor ligand activity inversion mutants: Receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens
-
Montano MM, Ekena K, Krueger KD, Keller AL, Katzenellenbogen BS: Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. Mol Endocrinol 10: 230-242, 1996
-
(1996)
Mol Endocrinol
, vol.10
, pp. 230-242
-
-
Montano, M.M.1
Ekena, K.2
Krueger, K.D.3
Keller, A.L.4
Katzenellenbogen, B.S.5
-
41
-
-
0029073127
-
Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists
-
Mahfoudi A, Roulet E, Dauvois S, Parker MG, Wahli W: Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci USA 92: 4206-4210, 1995
-
(1995)
Proc Natl Acad Sci USA
, vol.92
, pp. 4206-4210
-
-
Mahfoudi, A.1
Roulet, E.2
Dauvois, S.3
Parker, M.G.4
Wahli, W.5
-
42
-
-
2642593030
-
The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor
-
Levenson AS, Jordan VC: The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res 58: 1872-1875, 1999
-
(1999)
Cancer Res
, vol.58
, pp. 1872-1875
-
-
Levenson, A.S.1
Jordan, V.C.2
-
43
-
-
0028233383
-
Estrogen receptor-associated proteins: Possible mediators of hormone-induced transcription
-
Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M: Estrogen receptor-associated proteins: Possible mediators of hormone-induced transcription. Science 264: 1455-1458, 1994
-
(1994)
Science
, vol.264
, pp. 1455-1458
-
-
Halachmi, S.1
Marden, E.2
Martin, G.3
MacKay, H.4
Abbondanza, C.5
Brown, M.6
-
44
-
-
20244370996
-
The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways
-
Yu CL, Driggers P, Barrera-Hernandez G, Nunez SB, Segars JH, Cheng SY: The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways. Biochem Biophys Res Commun 239: 617-620, 1997
-
(1997)
Biochem Biophys Res Commun
, vol.239
, pp. 617-620
-
-
Yu, C.L.1
Driggers, P.2
Barrera-Hernandez, G.3
Nunez, S.B.4
Segars, J.H.5
Cheng, S.Y.6
-
45
-
-
0030949836
-
GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors
-
Hong H, Kohli K, Garabedian MJ, Stallcup MR: GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. Mol Cell Biol 17: 2735-2744, 1997
-
(1997)
Mol Cell Biol
, vol.17
, pp. 2735-2744
-
-
Hong, H.1
Kohli, K.2
Garabedian, M.J.3
Stallcup, M.R.4
-
46
-
-
0030946198
-
Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen
-
Smith CL, Nawaz Z, O'Malley BW: Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen, Mol Endocrinoi 11:657-666, 1997
-
(1997)
Mol Endocrinoi
, vol.11
, pp. 657-666
-
-
Smith, C.L.1
Nawaz, Z.2
O'Malley, B.W.3
-
47
-
-
0031611355
-
Transcriptional activation by oestrogen receptors
-
Parker MG: Transcriptional activation by oestrogen receptors. Biochem Soc Symp 63: 45-50, 1998
-
(1998)
Biochem Soc Symp
, vol.63
, pp. 45-50
-
-
Parker, M.G.1
-
48
-
-
0030797902
-
AIB1, a steroid receptor coactivator anplified in breast and ovarian cancer
-
Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS: AIB1, a steroid receptor coactivator anplified in breast and ovarian cancer. Science 277: 965-968, 1997
-
(1997)
Science
, vol.277
, pp. 965-968
-
-
Anzick, S.L.1
Kononen, J.2
Walker, R.L.3
Azorsa, D.O.4
Tanner, M.M.5
Guan, X.Y.6
Sauter, G.7
Kallioniemi, O.P.8
Trent, J.M.9
Meltzer, P.S.10
-
49
-
-
0032524634
-
The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation functionn 1 (AF1) and AF2 domains of steroid receptors
-
Onate SA, Boonyaratanakornkit V, Spencer TE, Tsai SY, Tsai MJ, Edwards DP, O'Malley BW: The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation functionn 1 (AF1) and AF2 domains of steroid receptors. J Biol Chem 273: 12101-12108, 1998
-
(1998)
J Biol Chem
, vol.273
, pp. 12101-12108
-
-
Onate, S.A.1
Boonyaratanakornkit, V.2
Spencer, T.E.3
Tsai, S.Y.4
Tsai, M.J.5
Edwards, D.P.6
O'Malley, B.W.7
-
50
-
-
0030998328
-
The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT
-
Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB: The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 11: 693-705, 1997
-
(1997)
Mol Endocrinol
, vol.11
, pp. 693-705
-
-
Jackson, T.A.1
Richer, J.K.2
Bain, D.L.3
Takimoto, G.S.4
Tung, L.5
Horwitz, K.B.6
-
51
-
-
0030333304
-
Epidemiology of susceptibility to breast cancer
-
Hulka BS: Epidemiology of susceptibility to breast cancer. Prog Clin Biol Res 395: 159-174, 1996
-
(1996)
Prog Clin Biol Res
, vol.395
, pp. 159-174
-
-
Hulka, B.S.1
-
52
-
-
0021132874
-
Correlation between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer
-
Clark GM, Osborne CK, McGuire WL: Correlation between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 2: 1102-1109, 1984
-
(1984)
J Clin Oncol
, vol.2
, pp. 1102-1109
-
-
Clark, G.M.1
Osborne, C.K.2
McGuire, W.L.3
-
53
-
-
50549123220
-
On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases
-
Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2: 104-107, 1896
-
(1896)
Lancet
, vol.2
, pp. 104-107
-
-
Beatson, G.T.1
-
54
-
-
0343618100
-
The role of major endocrine ablation
-
Stoll BA (ed) Yearbook Medical Publishers, Chicago
-
Robin PE, Dalton GA: The role of major endocrine ablation, In: Stoll BA (ed) Breast Cancer Early and Late. Yearbook Medical Publishers, Chicago, 1977, pp 147-156
-
(1977)
Breast Cancer Early and Late
, pp. 147-156
-
-
Robin, P.E.1
Dalton, G.A.2
-
55
-
-
0028861586
-
Use of tamoxifen for breast cancer: Twenty-eight years later
-
Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN: Use of tamoxifen for breast cancer: Twenty-eight years later. J Clin Oncol 13: 513-529, 1995
-
(1995)
J Clin Oncol
, vol.13
, pp. 513-529
-
-
Jaiyesimi, I.A.1
Buzdar, A.U.2
Decker, D.A.3
Hortobagyi, G.N.4
-
56
-
-
0020617897
-
Cell proliferation kinetics of MCF7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells
-
Sutherland RL, Hall RE, Taylor JW: Cell proliferation kinetics of MCF7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res 43: 3998-4006, 1983
-
(1983)
Cancer Res
, vol.43
, pp. 3998-4006
-
-
Sutherland, R.L.1
Hall, R.E.2
Taylor, J.W.3
-
57
-
-
0020606637
-
Effects of tamoxifen on human breast cancer cell kinetics: Accumulation of cells in early G1 phase
-
Osborne CK, Boldt DH, Clark GM, Trent JM: Effects of tamoxifen on human breast cancer cell kinetics: accumulation of cells in early G1 phase. Cancer Res 43: 3583-3585, 1983
-
(1983)
Cancer Res
, vol.43
, pp. 3583-3585
-
-
Osborne, C.K.1
Boldt, D.H.2
Clark, G.M.3
Trent, J.M.4
-
58
-
-
0024947505
-
Transforming growth factors in human breast cancer
-
Saloman DS, Ciardiello F, Valverius E, Saeki T, Kim N: Transforming growth factors in human breast cancer. Biomed Pharmacother 43: 661-667, 1989
-
(1989)
Biomed Pharmacother
, vol.43
, pp. 661-667
-
-
Saloman, D.S.1
Ciardiello, F.2
Valverius, E.3
Saeki, T.4
Kim, N.5
-
59
-
-
0029560348
-
Relationship between tamoxifen-induced transforming growth factor b1 expression cytostasis and apoptosis in human breast cancer cells
-
Perry RR, Kang Y, Greaves BR: Relationship between tamoxifen-induced transforming growth factor b1 expression cytostasis and apoptosis in human breast cancer cells. Br J Cancer 72: 1441-1446, 1995
-
(1995)
Br J Cancer
, vol.72
, pp. 1441-1446
-
-
Perry, R.R.1
Kang, Y.2
Greaves, B.R.3
-
60
-
-
0023625418
-
Evidence that transforming growth factor beta is a hormonally regulated negative growth factor in human breast cancer cells
-
Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB: Evidence that transforming growth factor beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48: 417-428, 1987
-
(1987)
Cell
, vol.48
, pp. 417-428
-
-
Knabbe, C.1
Lippman, M.E.2
Wakefield, L.M.3
Flanders, K.C.4
Kasid, A.5
Derynck, R.6
Dickson, R.B.7
-
61
-
-
0027373251
-
Regulation of the levels of three transforming growth factor mRNAs by estrogen and their effects on the proliferation of human breast cancer cells
-
Jeng MH, Ten Dijke P, Iwata KK, Jordan VC: Regulation of the levels of three transforming growth factor mRNAs by estrogen and their effects on the proliferation of human breast cancer cells. Mol Cell Endocrinol 97: 115-123, 1993
-
(1993)
Mol Cell Endocrinol
, vol.97
, pp. 115-123
-
-
Jeng, M.H.1
Ten Dijke, P.2
Iwata, K.K.3
Jordan, V.C.4
-
62
-
-
0030849605
-
Tamoxifen interferes with the insulin-like growth factor 1 receptor (IGF-1R) signaling pathway in breast cancer cells
-
Guvakova MA, Surmacz E: Tamoxifen interferes with the insulin-like growth factor 1 receptor (IGF-1R) signaling pathway in breast cancer cells. Cancer Res 57: 2606-2610, 1997
-
(1997)
Cancer Res
, vol.57
, pp. 2606-2610
-
-
Guvakova, M.A.1
Surmacz, E.2
-
63
-
-
0026591060
-
Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro
-
Antoniotti S, Maggiora P, Dati C, De Bortoli M: Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro. Eur J Cancer 28: 318-321, 1992
-
(1992)
Eur J Cancer
, vol.28
, pp. 318-321
-
-
Antoniotti, S.1
Maggiora, P.2
Dati, C.3
De Bortoli, M.4
-
64
-
-
0030060967
-
Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor(IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins
-
Kleinman D, Karas M, Danilenko M, Arbeli A, Roberts CT, Jr., LeRoith D, Levy J, Sharoni Y: Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor(IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins. Endocrinology 137: 1089-1095, 1996
-
(1996)
Endocrinology
, vol.137
, pp. 1089-1095
-
-
Kleinman, D.1
Karas, M.2
Danilenko, M.3
Arbeli, A.4
Roberts C.T., Jr.5
LeRoith, D.6
Levy, J.7
Sharoni, Y.8
-
65
-
-
0017078344
-
Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomas
-
Jordan VC: Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomas. Eur J Cancer 12: 419-424, 1976
-
(1976)
Eur J Cancer
, vol.12
, pp. 419-424
-
-
Jordan, V.C.1
-
66
-
-
0023229345
-
The antitumor action of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model
-
Gottardis MM, Jordan VC: The antitumor action of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47: 4020-4024, 1987
-
(1987)
Cancer Res
, vol.47
, pp. 4020-4024
-
-
Gottardis, M.M.1
Jordan, V.C.2
-
67
-
-
0027432309
-
Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780
-
Huynh HT, Pollak M: Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. Cancer Res 53: 5585-5588, 1993
-
(1993)
Cancer Res
, vol.53
, pp. 5585-5588
-
-
Huynh, H.T.1
Pollak, M.2
-
68
-
-
0029794465
-
Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen
-
Hyder SM, Stancel GM, Chiappetta C, Murthy L, Boettger-Tong HL, Makela S: Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Res 56: 3954-3960, 1996
-
(1996)
Cancer Res
, vol.56
, pp. 3954-3960
-
-
Hyder, S.M.1
Stancel, G.M.2
Chiappetta, C.3
Murthy, L.4
Boettger-Tong, H.L.5
Makela, S.6
-
69
-
-
0027325188
-
Down-regulation of transforming growth factor-a by tamoxifen in human breast cancer
-
Noguchi S, Motomura K, Inaji Y Imaoka S, Koyama H: Down-regulation of transforming growth factor-a by tamoxifen in human breast cancer. Cancer 72: 131-136, 1993
-
(1993)
Cancer
, vol.72
, pp. 131-136
-
-
Noguchi, S.1
Motomura, K.2
Inaji, Y.3
Imaoka, S.4
Koyama, H.5
-
70
-
-
0026775159
-
Induction of transforming growth factor b1 in human breast cancer in vivo following tamoxifen treatment
-
Butta A, MacLennan K, Flanders KC, Sacks NPM, Smith I, McKinna A, Dowsett M, Wakefield LM, Sporn MB, Baum M, Colletta AA: Induction of transforming growth factor b1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 52: 4261-4264, 1992
-
(1992)
Cancer Res
, vol.52
, pp. 4261-4264
-
-
Butta, A.1
MacLennan, K.2
Flanders, K.C.3
Sacks, N.P.M.4
Smith, I.5
McKinna, A.6
Dowsett, M.7
Wakefield, L.M.8
Sporn, M.B.9
Baum, M.10
Colletta, A.A.11
-
71
-
-
0027475326
-
Up-regulation of estrogen receptor by tamoxifen in human breast cancer
-
Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H: Up-regulation of estrogen receptor by tamoxifen in human breast cancer. Cancer 71: 1266-1272, 1993
-
(1993)
Cancer
, vol.71
, pp. 1266-1272
-
-
Noguchi, S.1
Motomura, K.2
Inaji, H.3
Imaoka, S.4
Koyama, H.5
-
72
-
-
0031881602
-
Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response
-
Makris A, Powles TJ, Allred DC, Ashley S, Ormerod MG, Titley JC, Dowsett M: Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. Breast Cancer Res Treat 48: 11-20, 1998
-
(1998)
Breast Cancer Res Treat
, vol.48
, pp. 11-20
-
-
Makris, A.1
Powles, T.J.2
Allred, D.C.3
Ashley, S.4
Ormerod, M.G.5
Titley, J.C.6
Dowsett, M.7
-
73
-
-
0026667688
-
Oestradiol synthesis from oestrone in malignant breast epithelial cells: Studies on a high affinity, 80 kDa form of oestradiol dehydrogenase
-
Newton CJ, Butta A, Nicholls J, Dowsett M: Oestradiol synthesis from oestrone in malignant breast epithelial cells: Studies on a high affinity, 80 kDa form of oestradiol dehydrogenase. J Steroid Biochem Mol Biol 42: 891-900, 1992
-
(1992)
J Steroid Biochem Mol Biol
, vol.42
, pp. 891-900
-
-
Newton, C.J.1
Butta, A.2
Nicholls, J.3
Dowsett, M.4
-
74
-
-
0019157188
-
Estrogen-receptor binding and biologic activity of tamoxifen and its metabolites
-
Wakeling AE, Slater SR: Estrogen-receptor binding and biologic activity of tamoxifen and its metabolites. Cancer Treat Rep 64: 741-744, 1980
-
(1980)
Cancer Treat Rep
, vol.64
, pp. 741-744
-
-
Wakeling, A.E.1
Slater, S.R.2
-
75
-
-
0021618186
-
The pharmacology and clinical uses of tamoxifen
-
Furr BS, Jordan VC: The pharmacology and clinical uses of tamoxifen. Phannacol Ther 25: 127-205, 1984
-
(1984)
Phannacol Ther
, vol.25
, pp. 127-205
-
-
Furr, B.S.1
Jordan, V.C.2
-
76
-
-
0015915672
-
Anti-oestrogen therapy for breast cancer: A trial of tamoxifen at two dose levels
-
Ward HWC: Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J 1: 13-14, 1973
-
(1973)
Br Med J
, vol.1
, pp. 13-14
-
-
Ward, H.W.C.1
-
77
-
-
0017565317
-
Tamoxifen (antiestrogen) therapy in advanced breast cancer
-
Kiang DT, Kennedy BJ: Tamoxifen (antiestrogen) therapy in advanced breast cancer. Am Intern Med 87: 687-690, 1977
-
(1977)
Am Intern Med
, vol.87
, pp. 687-690
-
-
Kiang, D.T.1
Kennedy, B.J.2
-
78
-
-
9844266794
-
A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer
-
Gershanovich M, Garin A, Baltina D, Kurvet A, Kangas L, Ellmen J, Eastern European Study group: A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat 45: 251-262, 1997
-
(1997)
Breast Cancer Res Treat
, vol.45
, pp. 251-262
-
-
Gershanovich, M.1
Garin, A.2
Baltina, D.3
Kurvet, A.4
Kangas, L.5
Ellmen, J.6
-
79
-
-
0031054478
-
Tamoxifen as initial endocrine therapy for metastatic breast cancer: Long term follow-up of two Piedmont Oncology Association (POA) trials
-
Kuss JT, Muss HB, Hoen H, Case LD: Tamoxifen as initial endocrine therapy for metastatic breast cancer: long term follow-up of two Piedmont Oncology Association (POA) trials. Breast Cancer Res Treat 42: 265-274, 1997
-
(1997)
Breast Cancer Res Treat
, vol.42
, pp. 265-274
-
-
Kuss, J.T.1
Muss, H.B.2
Hoen, H.3
Case, L.D.4
-
80
-
-
0031906362
-
Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer
-
Berns EMJJ, vanStaveren IL, Klijn JGM, Foekens JA: Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer. Breast Cancer Res Treat 48: 87-92, 1998
-
(1998)
Breast Cancer Res Treat
, vol.48
, pp. 87-92
-
-
Berns, E.M.J.J.1
VanStaveren, I.L.2
Klijn, J.G.M.3
Foekens, J.A.4
-
81
-
-
0030951877
-
Bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group Study
-
Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, Pugh R, Ciocca D, Ravdin P, O'Sullivan J, Rivkin S, Martino S, Osborne CK: bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group Study. J Clin Oncol 15: 1916-1922, 1997
-
(1997)
J Clin Oncol
, vol.15
, pp. 1916-1922
-
-
Elledge, R.M.1
Green, S.2
Howes, L.3
Clark, G.M.4
Berardo, M.5
Allred, D.C.6
Pugh, R.7
Ciocca, D.8
Ravdin, P.9
O'Sullivan, J.10
Rivkin, S.11
Martino, S.12
Osborne, C.K.13
-
82
-
-
0028360192
-
ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer
-
Borg Å, Baldetorp B, Fernö M, Killander D, Olsson H, Rydén S, Sigurdsson H: ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81: 137-144, 1994
-
(1994)
Cancer Lett
, vol.81
, pp. 137-144
-
-
Borg, Å.1
Baldetorp, B.2
Fernö, M.3
Killander, D.4
Olsson, H.5
Rydén, S.6
Sigurdsson, H.7
-
83
-
-
0032982818
-
Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
-
Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW: Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 79: 1220-1226, 1999
-
(1999)
Br J Cancer
, vol.79
, pp. 1220-1226
-
-
Houston, S.J.1
Plunkett, T.A.2
Barnes, D.M.3
Smith, P.4
Rubens, R.D.5
Miles, D.W.6
-
84
-
-
0031930148
-
HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study
-
Allred DC, Ciocca D, Clark GM, Elledge RM, Green S, Hill J, Martino S, O'Sullivan J, Osborne CK, Pugh R, Ravdin P: HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study. Clin Cancer Res 4: 7-12, 1998
-
(1998)
Clin Cancer Res
, vol.4
, pp. 7-12
-
-
Allred, D.C.1
Ciocca, D.2
Clark, G.M.3
Elledge, R.M.4
Green, S.5
Hill, J.6
Martino, S.7
O'Sullivan, J.8
Osborne, C.K.9
Pugh, R.10
Ravdin, P.11
-
85
-
-
0029021196
-
Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recwrrent breast cancer
-
Foekens JA, Look MP, Peters HA, Van Putten WLJ, Portengen H, Klijn JGM: Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recwrrent breast cancer. J Natl Cancer Inst 87: 751-756, 1995
-
(1995)
J Natl Cancer Inst
, vol.87
, pp. 751-756
-
-
Foekens, J.A.1
Look, M.P.2
Peters, H.A.3
Van Putten, W.L.J.4
Portengen, H.5
Klijn, J.G.M.6
-
86
-
-
0028099657
-
Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer
-
Foekens JA, Portengen H, Look MP, Van Putten WLJ, Thirion B, Bontenbal M, Klijn JGM: Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Br J Cancer 70: 1217-1223, 1994
-
(1994)
Br J Cancer
, vol.70
, pp. 1217-1223
-
-
Foekens, J.A.1
Portengen, H.2
Look, M.P.3
Van Putten, W.L.J.4
Thirion, B.5
Bontenbal, M.6
Klijn, J.G.M.7
-
87
-
-
0030860567
-
Expression of epidermal growth factor receptor and c-erbB-2 during the development of tamoxifen resistance in human breast cancer
-
Newby JC, Johnston SRD, Smith IE, Dowsett M: Expression of epidermal growth factor receptor and c-erbB-2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 3: 1643-1651, 1997
-
(1997)
Clin Cancer Res
, vol.3
, pp. 1643-1651
-
-
Newby, J.C.1
Johnston, S.2
Smith, I.E.3
Dowsett, M.4
-
88
-
-
0031982783
-
P53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer
-
Berns EMJJ, Klijn JGM, Van Putten WLJ, de Witte HH, Look MP, van Gelder MEM, Willman K, Portengen HW, Benraad TJ, Foekens JA: p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. J Clin Oncol 16: 121-127, 1998
-
(1998)
J Clin Oncol
, vol.16
, pp. 121-127
-
-
Berns, E.M.J.J.1
Klijn, J.G.M.2
Van Putten, W.L.J.3
De Witte, H.H.4
Look, M.P.5
Van Gelder, M.E.M.6
Willman, K.7
Portengen, H.W.8
Benraad, T.J.9
Foekens, J.A.10
-
89
-
-
0032940738
-
Endocrine response and resistance in breast cancer: A role for the transcription factor Fos
-
Gee JMW, Willsher PC, Kenny FS, Robertson JFR, Pinder SE, Ellis IO, Nicholson RI: Endocrine response and resistance in breast cancer: A role for the transcription factor Fos. Int J Cancer 84: 54-61, 1999
-
(1999)
Int J Cancer
, vol.84
, pp. 54-61
-
-
Gee, J.M.W.1
Willsher, P.C.2
Kenny, F.S.3
Robertson, J.F.R.4
Pinder, S.E.5
Ellis, I.O.6
Nicholson, R.I.7
-
90
-
-
0029781863
-
Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy
-
Kuukasjärvi T, Kononen J, Helin H, Holli K, Isola J: Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 14: 2584-2589, 1996
-
(1996)
J Clin Oncol
, vol.14
, pp. 2584-2589
-
-
Kuukasjärvi, T.1
Kononen, J.2
Helin, H.3
Holli, K.4
Isola, J.5
-
91
-
-
0032537396
-
Tamoxifen for early breast cancer: An overview of the randomised trials
-
Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467, 1998
-
(1998)
Lancet
, vol.351
, pp. 1451-1467
-
-
-
92
-
-
0033549344
-
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
-
Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, Kardinal CG, Kavanah MT, Fehrenbacher L, Oishi RH: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353: 1993-2000, 1999
-
(1999)
Lancet
, vol.353
, pp. 1993-2000
-
-
Fisher, B.1
Dignam, J.2
Wolmark, N.3
Wickerham, D.L.4
Fisher, E.R.5
Mamounas, E.6
Smith, R.7
Begovic, M.8
Dimitrov, N.V.9
Margolese, R.G.10
Kardinal, C.G.11
Kavanah, M.T.12
Fehrenbacher, L.13
Oishi, R.H.14
-
93
-
-
0032537990
-
Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
-
Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, TanChiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90: 1371-1388, 1998
-
(1998)
J Natl Cancer Inst
, vol.90
, pp. 1371-1388
-
-
Fisher, B.1
Costantino, J.P.2
Wickerham, D.L.3
Redmond, C.K.4
Kavanah, M.5
Cronin, W.M.6
Vogel, V.7
Robidoux, A.8
Dimitrov, N.9
Atkins, J.10
Daly, M.11
Wieand, S.12
TanChiu, E.13
Ford, L.14
Wolmark, N.15
-
94
-
-
0032508294
-
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
-
Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352: 98-101, 1998
-
(1998)
Lancet
, vol.352
, pp. 98-101
-
-
Powles, T.1
Eeles, R.2
Ashley, S.3
Easton, D.4
Chang, J.5
Dowsett, M.6
Tidy, A.7
Viggers, J.8
Davey, J.9
-
95
-
-
0032508293
-
Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomized women
-
Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P: Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomized women. Lancet 352: 93-97, 1998
-
(1998)
Lancet
, vol.352
, pp. 93-97
-
-
Veronesi, U.1
Maisonneuve, P.2
Costa, A.3
Sacchini, V.4
Maltoni, C.5
Robertson, C.6
Rotmensz, N.7
Boyle, P.8
-
96
-
-
0021356677
-
The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer
-
Gotfredsen A, Christiansen C, Palshof T: The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer. Cancer 53: 853-857, 1984
-
(1984)
Cancer
, vol.53
, pp. 853-857
-
-
Gotfredsen, A.1
Christiansen, C.2
Palshof, T.3
-
97
-
-
0032508227
-
Is tamoxifen effective in prevention of breast cancer?
-
Pritchard KI: Is tamoxifen effective in prevention of breast cancer? Lancet 352: 80-81, 1998
-
(1998)
Lancet
, vol.352
, pp. 80-81
-
-
Pritchard, K.I.1
-
98
-
-
0030792818
-
Innuence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women
-
Karp SE, Tonin PN, Begin LR, Martinez JJ, Zhang JC, Pollak MN, Foulkes WD: Innuence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 80: 435-441, 1997
-
(1997)
Cancer
, vol.80
, pp. 435-441
-
-
Karp, S.E.1
Tonin, P.N.2
Begin, L.R.3
Martinez, J.J.4
Zhang, J.C.5
Pollak, M.N.6
Foulkes, W.D.7
-
99
-
-
0032528215
-
Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes
-
Loman N, Johannsson O, Bendahl PO, Borg A, Ferno M, Olsson H: Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 83: 310-319, 1998
-
(1998)
Cancer
, vol.83
, pp. 310-319
-
-
Loman, N.1
Johannsson, O.2
Bendahl, P.O.3
Borg, A.4
Ferno, M.5
Olsson, H.6
-
100
-
-
0025936010
-
Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent
-
Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC: Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 83: 1488-1491, 1991
-
(1991)
J Natl Cancer Inst
, vol.83
, pp. 1488-1491
-
-
Jordan, V.C.1
Fritz, N.F.2
Langan-Fahey, S.3
Thompson, M.4
Tormey, D.C.5
-
101
-
-
0017190910
-
Effects of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women
-
Groom GV, Griffiths K: Effects of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocrinol 70: 421-428, 1976
-
(1976)
J Endocrinol
, vol.70
, pp. 421-428
-
-
Groom, G.V.1
Griffiths, K.2
-
102
-
-
0342460593
-
Ambiguous genitalia in infant exposed to tamoxifen in utero
-
Tewari K, Bonebrake RG, Asrat T, Shanberg AM: Ambiguous genitalia in infant exposed to tamoxifen in utero. Lancet 350: 183-183, 1997
-
(1997)
Lancet
, vol.350
, pp. 183-183
-
-
Tewari, K.1
Bonebrake, R.G.2
Asrat, T.3
Shanberg, A.M.4
-
103
-
-
0032941053
-
Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: Comparison between tamoxifen-treated and nontreated breast cancer patients
-
Cohen I, Figer A, Tepper R, Shapira J, Altaras MM, Yigael D, Beyth Y: Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: Comparison between tamoxifen-treated and nontreated breast cancer patients. Gynecol Oncol 72: 202-207, 1999
-
(1999)
Gynecol Oncol
, vol.72
, pp. 202-207
-
-
Cohen, I.1
Figer, A.2
Tepper, R.3
Shapira, J.4
Altaras, M.M.5
Yigael, D.6
Beyth, Y.7
-
104
-
-
0033040181
-
Ovarian cysts in women receiving tamoxifen for breast cancer
-
Mourits MJE, Devries EGE, Willemse PHB, tenHoor KA, Hollema H, Sluiter WJ, Debruijn HWA, Vanderzee AGJ: Ovarian cysts in women receiving tamoxifen for breast cancer. Br J Cancer 79: 1761-1764, 1999
-
(1999)
Br J Cancer
, vol.79
, pp. 1761-1764
-
-
Mourits, M.J.E.1
Devries, E.G.E.2
Willemse, P.H.B.3
TenHoor, K.A.4
Hollema, H.5
Sluiter, W.J.6
Debruijn, H.W.A.7
Vanderzee, A.G.J.8
-
105
-
-
0023146033
-
Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer
-
Jordan VC, Fritz NF, Tormey DC: Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res 47: 624-630, 1987
-
(1987)
Cancer Res
, vol.47
, pp. 624-630
-
-
Jordan, V.C.1
Fritz, N.F.2
Tormey, D.C.3
-
106
-
-
0032189241
-
Tamoxifen and proliferation of vaginal and cervical epithelium in postmenopausal women with breast cancer
-
Friedrich M, Mink D, VillenaHeinsen C, Wollhermann A, Schmidt W: Tamoxifen and proliferation of vaginal and cervical epithelium in postmenopausal women with breast cancer. Eur J Obstet Gynecol Reprod Biol 80: 221-225, 1998
-
(1998)
Eur J Obstet Gynecol Reprod Biol
, vol.80
, pp. 221-225
-
-
Friedrich, M.1
Mink, D.2
VillenaHeinsen, C.3
Wollhermann, A.4
Schmidt, W.5
-
108
-
-
0026779758
-
Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients
-
Lonning PE, Hall K, Aakvaag A, Lien EA: Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res 52: 4719-4723, 1992
-
(1992)
Cancer Res
, vol.52
, pp. 4719-4723
-
-
Lonning, P.E.1
Hall, K.2
Aakvaag, A.3
Lien, E.A.4
-
109
-
-
0026585852
-
Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
-
Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326: 852-856, 1992
-
(1992)
N Engl J Med
, vol.326
, pp. 852-856
-
-
Love, R.R.1
Mazess, R.B.2
Barden, H.S.3
Epstein, S.4
Newcomb, P.A.5
Jordan, V.C.6
Carbone, P.P.7
DeMets, D.L.8
-
110
-
-
0028212970
-
Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: A randomized study
-
Kristensen B, Ejlertsen B, Dalgaard P, Larsen L, Holmegaard SN, Transbol I, Mouridsen HT: Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: A randomized study. J Clin Oncol 12: 992-997, 1994
-
(1994)
J Clin Oncol
, vol.12
, pp. 992-997
-
-
Kristensen, B.1
Ejlertsen, B.2
Dalgaard, P.3
Larsen, L.4
Holmegaard, S.N.5
Transbol, I.6
Mouridsen, H.T.7
-
111
-
-
0030070093
-
Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women
-
Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S: Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14: 78-84, 1996
-
(1996)
J Clin Oncol
, vol.14
, pp. 78-84
-
-
Powles, T.J.1
Hickish, T.2
Kanis, J.A.3
Tidy, A.4
Ashley, S.5
-
112
-
-
0028000253
-
Effects of tamoxifen on cardiovascular risk factors in post-menopausal women after 5 years of treatment
-
Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ: Effects of tamoxifen on cardiovascular risk factors in post-menopausal women after 5 years of treatment. J Natl Cancer Inst 86: 1534-1539, 1995
-
(1995)
J Natl Cancer Inst
, vol.86
, pp. 1534-1539
-
-
Love, R.R.1
Wiebe, D.A.2
Feyzi, J.M.3
Newcomb, P.A.4
Chappell, R.J.5
-
113
-
-
0023265766
-
Cardiovascular mortality and noncontraceptive use of estrogens in women: Results from the Lipid Research Clinics Program Follow-up Study
-
Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM: Cardiovascular mortality and noncontraceptive use of estrogens in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 75: 1102-1109, 1987
-
(1987)
Circulation
, vol.75
, pp. 1102-1109
-
-
Bush, T.L.1
Barrett-Connor, E.2
Cowan, L.D.3
Criqui, M.H.4
Wallace, R.B.5
Suchindran, C.M.6
Tyroler, H.A.7
Rifkind, B.M.8
-
114
-
-
0027325734
-
Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of tamoxifen: The Stockholm Breast Cancer Study Group
-
Rutquist LE, Matteson A: Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of tamoxifen: the Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85: 1398-1406, 1993
-
(1993)
J Natl Cancer Inst
, vol.85
, pp. 1398-1406
-
-
Rutquist, L.E.1
Matteson, A.2
-
115
-
-
0025343030
-
Effects of tamoxifen treatment on plasma lipids and lipoprotein composition
-
Bagdade JD, Wolter J, Subbaiah PV, Ryan W: Effects of tamoxifen treatment on plasma lipids and lipoprotein composition. J Clin Endocrinol Metab 70: 1132-1135, 1990
-
(1990)
J Clin Endocrinol Metab
, vol.70
, pp. 1132-1135
-
-
Bagdade, J.D.1
Wolter, J.2
Subbaiah, P.V.3
Ryan, W.4
-
116
-
-
0021238933
-
Serum lipoprotein and proteins after breast cancer surgery and effects of tamoxifen
-
Rossner S, Wallgren A: Serum lipoprotein and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 53: 339-346, 1984
-
(1984)
Atherosclerosis
, vol.53
, pp. 339-346
-
-
Rossner, S.1
Wallgren, A.2
-
117
-
-
0030941737
-
Coronary heart disease mortality and adjuvant tamoxifen therapy
-
Costantino JP, Kuller LH, Ives DG, Fisher B, Dignam J: Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 89: 776-782, 1997
-
(1997)
J Natl Cancer Inst
, vol.89
, pp. 776-782
-
-
Costantino, J.P.1
Kuller, L.H.2
Ives, D.G.3
Fisher, B.4
Dignam, J.5
-
118
-
-
0026595133
-
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 Randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
-
Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 Randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 71-85, 1992
-
(1992)
Lancet
, vol.339
, pp. 71-85
-
-
-
119
-
-
0032542924
-
Tamoxifen for the prevention of breast cancer -important questions remain unanswered, and existing trials should continue
-
Bruzzi P: Tamoxifen for the prevention of breast cancer -important questions remain unanswered, and existing trials should continue. Br Med J 316: 1181-1182, 1998
-
(1998)
Br Med J
, vol.316
, pp. 1181-1182
-
-
Bruzzi, P.1
-
120
-
-
0028085970
-
Megestrol acetate for the prevention of hot flashes
-
Loprinzi CL, Michalak JC, Quella SK, O'Fallon JR, Hatfield AK, Nelimark RA, Dose AM, Fischer T, Johnson C, Klatt NE, Bate WW, Respond RM, Oesterling JE: Megestrol acetate for the prevention of hot flashes. N Engl J Med 331: 347-352, 1994
-
(1994)
N Engl J Med
, vol.331
, pp. 347-352
-
-
Loprinzi, C.L.1
Michalak, J.C.2
Quella, S.K.3
O'Fallon, J.R.4
Hatfield, A.K.5
Nelimark, R.A.6
Dose, A.M.7
Fischer, T.8
Johnson, C.9
Klatt, N.E.10
Bate, W.W.11
Respond, R.M.12
Oesterling, J.E.13
-
121
-
-
0031917063
-
Prospective evaluation of vitamin e for hot flashes in breast cancer survivors
-
Barton DL, Loprinzi CL, Quella SK, Sloan JA, Veeder MH, Egner JR, Fidler P, Stella PJ, Swan DK, Vaught NL, Novotny P: Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 16: 495-500, 1998
-
(1998)
J Clin Oncol
, vol.16
, pp. 495-500
-
-
Barton, D.L.1
Loprinzi, C.L.2
Quella, S.K.3
Sloan, J.A.4
Veeder, M.H.5
Egner, J.R.6
Fidler, P.7
Stella, P.J.8
Swan, D.K.9
Vaught, N.L.10
Novotny, P.11
-
122
-
-
0026606580
-
Induction of covalent DNA adducts in rodents by tamoxifen
-
Han X, Liehr JG: Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 52: 1360-1363, 1992
-
(1992)
Cancer Res
, vol.52
, pp. 1360-1363
-
-
Han, X.1
Liehr, J.G.2
-
123
-
-
0029745072
-
Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients
-
Hemminki K, Rajaniemi H, Lindahl B, Moberger B: Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res 56: 4374-4377, 1996
-
(1996)
Cancer Res
, vol.56
, pp. 4374-4377
-
-
Hemminki, K.1
Rajaniemi, H.2
Lindahl, B.3
Moberger, B.4
-
124
-
-
0030899189
-
Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus
-
Li DH, Dragan Y, Jordan VC, Wang MY, Pitot HC: Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus. Cancer Res 57: 1438-1441, 1997
-
(1997)
Cancer Res
, vol.57
, pp. 1438-1441
-
-
Li, D.H.1
Dragan, Y.2
Jordan, V.C.3
Wang, M.Y.4
Pitot, H.C.5
-
125
-
-
0033135051
-
Mutagenic potential of a-(N2-deoxyguanosinyl)tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen
-
Terashima I, Suzuki N, Shibutani S: Mutagenic potential of a-(N2-deoxyguanosinyl)tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen. Cancer Res 59: 2091-2095, 1999
-
(1999)
Cancer Res
, vol.59
, pp. 2091-2095
-
-
Terashima, I.1
Suzuki, N.2
Shibutani, S.3
-
126
-
-
0027412216
-
High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients
-
Magriples U, Naftolin F, Schwartz PE, Carcangiu ML: High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 11: 485-490, 1993
-
(1993)
J Clin Oncol
, vol.11
, pp. 485-490
-
-
Magriples, U.1
Naftolin, F.2
Schwartz, P.E.3
Carcangiu, M.L.4
-
127
-
-
0028287647
-
Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial
-
Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S: Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343: 1318-1321, 1994
-
(1994)
Lancet
, vol.343
, pp. 1318-1321
-
-
Kedar, R.P.1
Bourne, T.H.2
Powles, T.J.3
Collins, W.P.4
Ashley, S.E.5
Cosgrove, D.O.6
Campbell, S.7
-
128
-
-
0031052184
-
Tamoxifen and endometrial cancer: Tamoxifen effects on the human female genital tract
-
Cohen CJ: Tamoxifen and endometrial cancer: tamoxifen effects on the human female genital tract. Semin Oncol 24: S1-55-S1-64, 1997
-
(1997)
Semin Oncol
, vol.24
-
-
Cohen, C.J.1
-
129
-
-
0027299818
-
Endometrial changes in post-menopausal breast cancer patients receiving tamoxifen
-
Lahti E, Bianco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T: Endometrial changes in post-menopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 81: 660-664, 1993
-
(1993)
Obstet Gynecol
, vol.81
, pp. 660-664
-
-
Lahti, E.1
Bianco, G.2
Kauppila, A.3
Apaja-Sarkkinen, M.4
Taskinen, P.J.5
Laatikainen, T.6
-
130
-
-
0030915027
-
Transvaginal sonographic and hysteroscopic findings in postmenopausal women receiving tamoxifen
-
Marconi D, Exacoustos C, Cangi B, Perroni A, Zupi E, Valli E, Romanini C: Transvaginal sonographic and hysteroscopic findings in postmenopausal women receiving tamoxifen. J Am Assoc Gynecol Laparosc 4: 331-339, 1997
-
(1997)
J am Assoc Gynecol Laparosc
, vol.4
, pp. 331-339
-
-
Marconi, D.1
Exacoustos, C.2
Cangi, B.3
Perroni, A.4
Zupi, E.5
Valli, E.6
Romanini, C.7
-
131
-
-
0031214148
-
Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients
-
Cheng WF, Lin HH, Torng PL, Huang SC: Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol 66: 233-237, 1997
-
(1997)
Gynecol Oncol
, vol.66
, pp. 233-237
-
-
Cheng, W.F.1
Lin, H.H.2
Torng, P.L.3
Huang, S.C.4
-
132
-
-
0031104744
-
Value of sonohysterography in asymptomatic postmenopausal tamoxifen-treated patients
-
Tepper R, Beyth Y, Altaras MM, Zalel Y, Shapira J, Cordoba M, Cohen I: Value of sonohysterography in asymptomatic postmenopausal tamoxifen-treated patients. Gynecol Oncol 64: 386-391, 1997
-
(1997)
Gynecol Oncol
, vol.64
, pp. 386-391
-
-
Tepper, R.1
Beyth, Y.2
Altaras, M.M.3
Zalel, Y.4
Shapira, J.5
Cordoba, M.6
Cohen, I.7
-
133
-
-
0031468255
-
Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease
-
Langer RD, Pierce JJ, O'Hanlan KA, Johnson SR, Espeland MA, Trabal JF, Barnabei VM, Merino MJ, Scully RE: Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. N Engl J Med 337: 1792-1798, 1997
-
(1997)
N Engl J Med
, vol.337
, pp. 1792-1798
-
-
Langer, R.D.1
Pierce, J.J.2
O'Hanlan, K.A.3
Johnson, S.R.4
Espeland, M.A.5
Trabal, J.F.6
Barnabei, V.M.7
Merino, M.J.8
Scully, R.E.9
-
134
-
-
0031746719
-
Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy
-
McGonigle KF, Shaw SL, Vasilev SA, Odom-Maryon T, Roy S, Simpson JF: Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. Am J Obstet Gynecol 178: 1145-1150, 1998
-
(1998)
Am J Obstet Gynecol
, vol.178
, pp. 1145-1150
-
-
McGonigle, K.F.1
Shaw, S.L.2
Vasilev, S.A.3
Odom-Maryon, T.4
Roy, S.5
Simpson, J.F.6
-
135
-
-
6844240215
-
Tamoxifen and the endometrium: Findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients
-
Bertelli G, Cosso M, Cusimano E, Delmastro L, Garrone O, Guide T, Gustavino C, Nicolo G, Rosso A, Venturini M: Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Res Treat 47: 41-46, 1998
-
(1998)
Breast Cancer Res Treat
, vol.47
, pp. 41-46
-
-
Bertelli, G.1
Cosso, M.2
Cusimano, E.3
Delmastro, L.4
Garrone, O.5
Guide, T.6
Gustavino, C.7
Nicolo, G.8
Rosso, A.9
Venturini, M.10
-
136
-
-
0031946885
-
Tamoxifen associated uterine pathology in breast cancer patients with abnormal bleeding
-
Fotiou S, Tserkezoglou A, Hadjieleftheriou G, Apostolikas N, Karydas I, Stravolemos K: Tamoxifen associated uterine pathology in breast cancer patients with abnormal bleeding. Anticancer Res 18: 625-630, 1998
-
(1998)
Anticancer Res
, vol.18
, pp. 625-630
-
-
Fotiou, S.1
Tserkezoglou, A.2
Hadjieleftheriou, G.3
Apostolikas, N.4
Karydas, I.5
Stravolemos, K.6
-
138
-
-
0019319147
-
Tamoxifen and thromboembolism
-
Hendrick A, Sebramanian VP: Tamoxifen and thromboembolism. JAMA 243: 514-515, 1980
-
(1980)
JAMA
, vol.243
, pp. 514-515
-
-
Hendrick, A.1
Sebramanian, V.P.2
-
139
-
-
0026014191
-
Adjuvant tamoxifen in early-stage breast cancer: Effects on intercurrent morbidity and mortality
-
Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Skoog L, Somell A, Theve T, Wilking N, Askergren J, Rotstein S, Hjalmar M-L, Perbeck L: Adjuvant tamoxifen in early-stage breast cancer: Effects on intercurrent morbidity and mortality. J Clin Oncol 9: 1740-1748, 1991
-
(1991)
J Clin Oncol
, vol.9
, pp. 1740-1748
-
-
Fornander, T.1
Rutqvist, L.E.2
Cedermark, B.3
Glas, U.4
Mattsson, A.5
Skoog, L.6
Somell, A.7
Theve, T.8
Wilking, N.9
Askergren, J.10
Rotstein, S.11
Hjalmar, M.-L.12
Perbeck, L.13
-
140
-
-
0027998596
-
Protein S and protein C level changes with adjuvant tamoxifen therapy in post-menopausal women
-
Mamby CC, Love RR, Feyzi JM: Protein S and protein C level changes with adjuvant tamoxifen therapy in post-menopausal women. Breast Cancer Res Treat 30: 311-314, 1994
-
(1994)
Breast Cancer Res Treat
, vol.30
, pp. 311-314
-
-
Mamby, C.C.1
Love, R.R.2
Feyzi, J.M.3
-
141
-
-
0021255302
-
Tamoxifen treatment of metastatic breast cancer and antithrombin III levels
-
Enck RE, Rios CM; Tamoxifen treatment of metastatic breast cancer and antithrombin III levels. Cancer 53: 2607-2609, 1984
-
(1984)
Cancer
, vol.53
, pp. 2607-2609
-
-
Enck, R.E.1
Rios, C.M.2
-
142
-
-
0023868350
-
Effects of tamoxifen in blood coagulation
-
Auger MJ, Mackle MJ: Effects of tamoxifen in blood coagulation. Cancer 61: 1316-1319, 1988
-
(1988)
Cancer
, vol.61
, pp. 1316-1319
-
-
Auger, M.J.1
Mackle, M.J.2
-
143
-
-
0029995266
-
Tamoxifen-associated eye disease: A review
-
Mayfield SG, Gorin MB: Tamoxifen-associated eye disease: a review. J Clin Oncol 14: 1018-1026, 1996
-
(1996)
J Clin Oncol
, vol.14
, pp. 1018-1026
-
-
Mayfield, S.G.1
Gorin, M.B.2
-
144
-
-
0023760993
-
Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration
-
Gottardis MM, Jordan VC: Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48: 5183-5187, 1988
-
(1988)
Cancer Res
, vol.48
, pp. 5183-5187
-
-
Gottardis, M.M.1
Jordan, V.C.2
-
145
-
-
0023642827
-
Clinical significance of tamoxifen withdrawal response
-
Canney PA, Griffiths T, Latief TN, Priestman TJ: Clinical significance of tamoxifen withdrawal response. Lancet 1: 36, 1987
-
(1987)
Lancet
, vol.1
, pp. 36
-
-
Canney, P.A.1
Griffiths, T.2
Latief, T.N.3
Priestman, T.J.4
-
146
-
-
10344238569
-
Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
-
Fisher B, Dignam J, Bryant J, Decillis A, Wickerham DL, Wolmark N, Constantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AHG, Feldman MI, Farrar W, Evens J, Lickley HL: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88: 1529-1542, 1996
-
(1996)
J Natl Cancer Inst
, vol.88
, pp. 1529-1542
-
-
Fisher, B.1
Dignam, J.2
Bryant, J.3
Decillis, A.4
Wickerham, D.L.5
Wolmark, N.6
Constantino, J.7
Redmond, C.8
Fisher, E.R.9
Bowman, D.M.10
Deschenes, L.11
Dimitrov, N.V.12
Margolese, R.G.13
Robidoux, A.14
Shibata, H.15
Terz, J.16
Paterson, A.H.G.17
Feldman, M.I.18
Farrar, W.19
Evens, J.20
Lickley, H.L.21
more..
-
147
-
-
0027762610
-
Type I ICF receptor and acquired tamoxifen resistance in oestrogen-repponsive human breast cancer cells
-
Wiseman LR, Johnson MD, Wakeling AE, Lykkesfeldt AE, May FEB, Westley BR: Type I ICF receptor and acquired tamoxifen resistance in oestrogen-repponsive human breast cancer cells. Eur J Cancer 29A: 2256-2264, 1993
-
(1993)
Eur J Cancer
, vol.29 A
, pp. 2256-2264
-
-
Wiseman, L.R.1
Johnson, M.D.2
Wakeling, A.E.3
Lykkesfeldt, A.E.4
May, F.E.B.5
Westley, B.R.6
-
148
-
-
0027435039
-
Measurement of steroid hormone receptors in breast cancer patients on tamoxifen
-
Encarnación CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SAW, Osborne CK: Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 26: 237-246, 1993
-
(1993)
Breast Cancer Res Treat
, vol.26
, pp. 237-246
-
-
Encarnación, C.A.1
Ciocca, D.R.2
McGuire, W.L.3
Clark, G.M.4
Fuqua, S.A.W.5
Osborne, C.K.6
-
149
-
-
0029113686
-
Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer
-
Johnston SRD, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR, Dowsett M: Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 55: 3331-3338, 1495
-
(1495)
Cancer Res
, vol.55
, pp. 3331-3338
-
-
Johnston, S.R.D.1
Saccani-Jotti, G.2
Smith, I.E.3
Salter, J.4
Newby, J.5
Coppen, M.6
Ebbs, S.R.7
Dowsett, M.8
-
150
-
-
0030734795
-
Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: Evidence that an open pocket conformation is required for ligand interaction
-
Carlson KE, Choi I, Gee A, Katzenellenbogen BS, Katzenellenbogen JA: Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry 36: 14897-14905, 1997
-
(1997)
Biochemistry
, vol.36
, pp. 14897-14905
-
-
Carlson, K.E.1
Choi, I.2
Gee, A.3
Katzenellenbogen, B.S.4
Katzenellenbogen, J.A.5
-
151
-
-
0032031082
-
Ligand-independent activation of the estrogen receptors alpha and beta by mutations of a conserved tyrosine can be abolished by antiestrogens
-
Tremblay GB, Tremblay A, Labrie F, Giguere V: Ligand-independent activation of the estrogen receptors alpha and beta by mutations of a conserved tyrosine can be abolished by antiestrogens. Cancer Res 58: 877-881, 1998
-
(1998)
Cancer Res
, vol.58
, pp. 877-881
-
-
Tremblay, G.B.1
Tremblay, A.2
Labrie, F.3
Giguere, V.4
-
152
-
-
0028006308
-
Estrogen receptor mutations in tamoxifen-resistant breast cancer
-
Karnik PS, Kulkami S, Liu X-P, Budd GT, Bukowski RM: Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 54: 349-353, 1994
-
(1994)
Cancer Res
, vol.54
, pp. 349-353
-
-
Karnik, P.S.1
Kulkami, S.2
Liu, X.-P.3
Budd, G.T.4
Bukowski, R.M.5
-
153
-
-
0027219768
-
Investigation of the origin of variant, truncated estrogen receptor-like mRNAs identified in some human breast cancer biopsy samples
-
Murphy LC, Dotzlaw H, Hamerton J, Schwarz J: Investigation of the origin of variant, truncated estrogen receptor-like mRNAs identified in some human breast cancer biopsy samples. Breast Cancer Res Treat 26: 149-161, 1993
-
(1993)
Breast Cancer Res Treat
, vol.26
, pp. 149-161
-
-
Murphy, L.C.1
Dotzlaw, H.2
Hamerton, J.3
Schwarz, J.4
-
154
-
-
0032052806
-
The pathophysiological role of estrogen receptor variants in human breast cancer
-
Murphy LC, Dotzlaw H, Leygue E, Coutts A, Watson P: The pathophysiological role of estrogen receptor variants in human breast cancer. J Steroid Biochem Mol Biol 65: 175-180, 1998
-
(1998)
J Steroid Biochem Mol Biol
, vol.65
, pp. 175-180
-
-
Murphy, L.C.1
Dotzlaw, H.2
Leygue, E.3
Coutts, A.4
Watson, P.5
-
155
-
-
0025967295
-
Variant human breast tumor estrogen receptor with constitutive transcriptional activity
-
Fuqua SAW, Fitzgerald SD, Chamness GC, Tandon AK, McDonnell DP, Nawaz Z, O'Malley BW, McGuire WL: Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 51: 105-109, 1991
-
(1991)
Cancer Res
, vol.51
, pp. 105-109
-
-
Fuqua, S.A.W.1
Fitzgerald, S.D.2
Chamness, G.C.3
Tandon, A.K.4
McDonnell, D.P.5
Nawaz, Z.6
O'Malley, B.W.7
McGuire, W.L.8
-
156
-
-
0027146672
-
Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line
-
Castles CG, Fuqua SAW, Klotz DM, Hill SM: Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res 53: 5934-5939, 1993
-
(1993)
Cancer Res
, vol.53
, pp. 5934-5939
-
-
Castles, C.G.1
Fuqua, S.A.W.2
Klotz, D.M.3
Hill, S.M.4
-
157
-
-
0026570643
-
Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors
-
Fuqua SAW, Fitzgerald SD, Allred DC, Elledge RM, Nawaz Z, McDonnell DP, O'Malley BW, Greene GL, McGuire WL: Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res 52: 483-486, 1992
-
(1992)
Cancer Res
, vol.52
, pp. 483-486
-
-
Fuqua, S.A.W.1
Fitzgerald, S.D.2
Allred, D.C.3
Elledge, R.M.4
Nawaz, Z.5
McDonnell, D.P.6
O'Malley, B.W.7
Greene, G.L.8
McGuire, W.L.9
-
158
-
-
0029738763
-
Prevalence of estrogen receptor variant messenger RNAs in human breast cancer
-
Leygue E, Huang AH Murphy LC, Watson PH: Prevalence of estrogen receptor variant messenger RNAs in human breast cancer. Cancer Res 56: 4324-4327, 1996
-
(1996)
Cancer Res
, vol.56
, pp. 4324-4327
-
-
Leygue, E.1
Huang, A.H.2
Murphy, L.C.3
Watson, P.H.4
-
159
-
-
0030292856
-
Multiple splicing variants of the estrogen receptor are present in individual human breast tumors
-
Zhang QX, Hilsenbeck SG, Fuqua SAW, Borg A: Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. J Steroid Biochem Mol Biol 59: 251-260, 1996
-
(1996)
J Steroid Biochem Mol Biol
, vol.59
, pp. 251-260
-
-
Zhang, Q.X.1
Hilsenbeck, S.G.2
Fuqua, S.A.W.3
Borg, A.4
-
160
-
-
0028795855
-
Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer
-
Daffada AAI, Johnston SRD, Smith EE, Detre S, King N, Dowsett M: Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. Cancer Res 55: 288-293, 1995
-
(1995)
Cancer Res
, vol.55
, pp. 288-293
-
-
Daffada, A.A.I.1
Johnston, S.R.D.2
Smith, E.E.3
Detre, S.4
King, N.5
Dowsett, M.6
-
161
-
-
0028049163
-
Characterization of ligand-dependent phosphorylation of the estrogen receptor
-
Lahooti H, White R, Danielian PS, Parker MG: Characterization of ligand-dependent phosphorylation of the estrogen receptor. Mol Endocrinol 8: 182-188, 1994
-
(1994)
Mol Endocrinol
, vol.8
, pp. 182-188
-
-
Lahooti, H.1
White, R.2
Danielian, P.S.3
Parker, M.G.4
-
162
-
-
0028800721
-
Prolonged treatment of breast cancer cells with antiestrogens increases the activating protein-1-mediated response: Involvement of the estrogen receptor
-
Astruc ME, Chabret C, Bali P, Gagne D, Pens M: Prolonged treatment of breast cancer cells with antiestrogens increases the activating protein-1-mediated response: Involvement of the estrogen receptor. Endocrinology 136: 824-832, 1995
-
(1995)
Endocrinology
, vol.136
, pp. 824-832
-
-
Astruc, M.E.1
Chabret, C.2
Bali, P.3
Gagne, D.4
Pens, M.5
-
163
-
-
0029802492
-
Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity
-
Dumont JA, Bitoni AJ, Wallace CD, Baumann RJ, Cashman EA, Cross-Doersen DE: Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ 7: 351-359, 1996
-
(1996)
Cell Growth Differ
, vol.7
, pp. 351-359
-
-
Dumont, J.A.1
Bitoni, A.J.2
Wallace, C.D.3
Baumann, R.J.4
Cashman, E.A.5
Cross-Doersen, D.E.6
-
164
-
-
0033049975
-
Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance
-
Johnston SRD, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M, Benz CC: Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res 5: 251-256, 1999
-
(1999)
Clin Cancer Res
, vol.5
, pp. 251-256
-
-
Johnston, S.R.D.1
Lu, B.2
Scott, G.K.3
Kushner, P.J.4
Smith, I.E.5
Dowsett, M.6
Benz, C.C.7
-
165
-
-
0030819407
-
Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogenresistant human breast tumors
-
Johnston SRD, Lu B, Dowsett M, Liang X, Kaufmann M, Scott GK, Osborne CK, Benz CC: Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogenresistant human breast tumors. Cancer Res 57: 3723-3727, 1997
-
(1997)
Cancer Res
, vol.57
, pp. 3723-3727
-
-
Johnston, S.R.D.1
Lu, B.2
Dowsett, M.3
Liang, X.4
Kaufmann, M.5
Scott, G.K.6
Osborne, C.K.7
Benz, C.C.8
-
166
-
-
0026068370
-
Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen
-
Osborne CK, Coronado E, Alfred DC, Wiebe V, DeGregorio M: Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 83: 1477-1482, 1991
-
(1991)
J Natl Cancer Inst
, vol.83
, pp. 1477-1482
-
-
Osborne, C.K.1
Coronado, E.2
Alfred, D.C.3
Wiebe, V.4
DeGregorio, M.5
-
167
-
-
0026580111
-
Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients
-
Osborne CK, Wiebe VJ, McGuire WL, Ciocca DR, DeGregorio MW: Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol 10: 304-310, 1992
-
(1992)
J Clin Oncol
, vol.10
, pp. 304-310
-
-
Osborne, C.K.1
Wiebe, V.J.2
McGuire, W.L.3
Ciocca, D.R.4
DeGregorio, M.W.5
-
168
-
-
0026632964
-
Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors
-
Wiebe VJ, Osborne CK, McGuire WL, DeGregorio MW: Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. J Clin Oncol 10: 990-994, 1992
-
(1992)
J Clin Oncol
, vol.10
, pp. 990-994
-
-
Wiebe, V.J.1
Osborne, C.K.2
McGuire, W.L.3
DeGregorio, M.W.4
-
169
-
-
0027280831
-
Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites
-
Wolf DM, Langan-Fahey SM, Parker CJ, McCague R, Jordan VC: Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites. J Natl Cancer Inst 85: 806-812, 1993
-
(1993)
J Natl Cancer Inst
, vol.85
, pp. 806-812
-
-
Wolf, D.M.1
Langan-Fahey, S.M.2
Parker, C.J.3
McCague, R.4
Jordan, V.C.5
-
170
-
-
0028246412
-
The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth
-
Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG, Wakeling AE: The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 34: 89-95, 1984
-
(1984)
Cancer Chemother Pharmacol
, vol.34
, pp. 89-95
-
-
Osborne, C.K.1
Jarman, M.2
McCague, R.3
Coronado, E.B.4
Hilsenbeck, S.G.5
Wakeling, A.E.6
-
171
-
-
0025251643
-
Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer
-
Langan-Fahey SM, Tormey DC, Jordan VC: Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer 26: 883-888, 1990
-
(1990)
Eur J Cancer
, vol.26
, pp. 883-888
-
-
Langan-Fahey, S.M.1
Tormey, D.C.2
Jordan, V.C.3
-
172
-
-
0027185314
-
Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: Identification of bcar-1, a common integration site
-
Dorssers LCJ, van Agthoven T, Dekker A, Van Agthoven TLA, Kok EM: Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: Identification of bcar-1, a common integration site. Mol Endocrinol 7: 870-878, 1993
-
(1993)
Mol Endocrinol
, vol.7
, pp. 870-878
-
-
Dorssers, L.C.J.1
Van Agthoven, T.2
Dekker, A.3
Van Agthoven, T.L.A.4
Kok, E.M.5
-
173
-
-
0032525138
-
Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells
-
van Agthoven T, Van Agthoven TLA, Dekker A, van der Spek PJ, Vreede L, Dorssers LCJ: Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. EMBO J 17: 2799-2808, 1998
-
(1998)
EMBO J
, vol.17
, pp. 2799-2808
-
-
Van Agthoven, T.1
Van Agthoven, T.L.A.2
Dekker, A.3
Van Der Spek, P.J.4
Vreede, L.5
Dorssers, L.C.J.6
-
174
-
-
0031026744
-
Clinical potential of new anti-estrogens
-
Gradishar WJ, Jordan VC: Clinical potential of new anti-estrogens. J Clin Oncol 15: 840-852, 1997
-
(1997)
J Clin Oncol
, vol.15
, pp. 840-852
-
-
Gradishar, W.J.1
Jordan, V.C.2
-
175
-
-
0032126037
-
In search of the perfect SERM: Beyond tamoxifen and raloxifene
-
McNeil C: In search of the perfect SERM: Beyond tamoxifen and raloxifene. J Natl Cancer Inst 90: 956-957, 1998
-
(1998)
J Natl Cancer Inst
, vol.90
, pp. 956-957
-
-
McNeil, C.1
-
176
-
-
0022468280
-
A new triphenylethylene compound Fc-1157A. II antitumor effects
-
Kangas L, Neiminen A-L, Bianco G, Gronroos M, Kattio S, Karjalainen A, Perilla M, Sodervall M, Tiovola R: A new triphenylethylene compound Fc-1157A. II antitumor effects. Cancer Chemother Pharmacol 17: 109-113, 1986
-
(1986)
Cancer Chemother Pharmacol
, vol.17
, pp. 109-113
-
-
Kangas, L.1
Neiminen, A.-L.2
Bianco, G.3
Gronroos, M.4
Kattio, S.5
Karjalainen, A.6
Perilla, M.7
Sodervall, M.8
Tiovola, R.9
-
177
-
-
0027428568
-
Major differences in the hep-atocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD (BR) rats
-
Hard GC, Iatropoulos MJ, Jordan K, Radi L, Kaltenberg OP, Imondi AR, Williams GM: Major differences in the hep-atocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD (BR) rats. Cancer Res 53: 4534-4541, 1993
-
(1993)
Cancer Res
, vol.53
, pp. 4534-4541
-
-
Hard, G.C.1
Iatropoulos, M.J.2
Jordan, K.3
Radi, L.4
Kaltenberg, O.P.5
Imondi, A.R.6
Williams, G.M.7
-
178
-
-
2642657654
-
Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: A randomized double-blind, the "nordic" phase III study
-
Pyrhonen S, Valavaara R, Modig H, Pawlicki M, Pienkowski T, Gundersen S, Bauer J, Westman G, Lundgren S, Bianco G, Mella O, Nilsson I, Hietanen T, Hindy I, Vuorinen J, Hajba A: Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the "nordic" phase III study. Br J Cancer 76: 270-277, 1997
-
(1997)
Br J Cancer
, vol.76
, pp. 270-277
-
-
Pyrhonen, S.1
Valavaara, R.2
Modig, H.3
Pawlicki, M.4
Pienkowski, T.5
Gundersen, S.6
Bauer, J.7
Westman, G.8
Lundgren, S.9
Bianco, G.10
Mella, O.11
Nilsson, I.12
Hietanen, T.13
Hindy, I.14
Vuorinen, J.15
Hajba, A.16
-
179
-
-
0029084658
-
Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer
-
Hayes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, Jones SE, Vogel CL, Berris RF, Shemano I, Schoenfelder J: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13: 2556-2566, 1995
-
(1995)
J Clin Oncol
, vol.13
, pp. 2556-2566
-
-
Hayes, D.F.1
Van Zyl, J.A.2
Hacking, A.3
Goedhals, L.4
Bezwoda, W.R.5
Mailliard, J.A.6
Jones, S.E.7
Vogel, C.L.8
Berris, R.F.9
Shemano, I.10
Schoenfelder, J.11
-
180
-
-
0027409546
-
Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer
-
Vogel CL, Shemano I, Schoenfelder J, Gams RA, Green MR: Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J Clin Oncol 11: 345-350, 1993
-
(1993)
J Clin Oncol
, vol.11
, pp. 345-350
-
-
Vogel, C.L.1
Shemano, I.2
Schoenfelder, J.3
Gams, R.A.4
Green, M.R.5
-
181
-
-
0032556191
-
Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth
-
O'Regan RM, Cisneros A, England GM, MacGregor JI, Muenznar HD, Assikis VJ, Bilimoria MM, Piette M, Dragan YP, Pilot HC, Chatterton R, Jordan VC: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst 90: 1552-1558, 1998
-
(1998)
J Natl Cancer Inst
, vol.90
, pp. 1552-1558
-
-
O'Regan, R.M.1
Cisneros, A.2
England, G.M.3
MacGregor, J.I.4
Muenznar, H.D.5
Assikis, V.J.6
Bilimoria, M.M.7
Piette, M.8
Dragan, Y.P.9
Pilot, H.C.10
Chatterton, R.11
Jordan, V.C.12
-
182
-
-
0028793801
-
Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients
-
Tomas E, Kauppila A, Blanco G, Apaja-Sarkkinen M, Laatikainen T: Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol 59: 241-266, 1995
-
(1995)
Gynecol Oncol
, vol.59
, pp. 241-266
-
-
Tomas, E.1
Kauppila, A.2
Blanco, G.3
Apaja-Sarkkinen, M.4
Laatikainen, T.5
-
183
-
-
0032052776
-
Antiestrogen stimulated human endometrial cancer growth: Laboratory and clinical considerations
-
Tonetti DA, O'Regan R, Tanjore S, England G, Jordan VC: Antiestrogen stimulated human endometrial cancer growth: Laboratory and clinical considerations. J Steroid Biochem Mol Biol 65: 181-189, 1998
-
(1998)
J Steroid Biochem Mol Biol
, vol.65
, pp. 181-189
-
-
Tonetti, D.A.1
O'Regan, R.2
Tanjore, S.3
England, G.4
Jordan, V.C.5
-
184
-
-
0031764190
-
Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients
-
Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O: Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 83: 1158-1162, 1998
-
(1998)
J Clin Endocrinol Metab
, vol.83
, pp. 1158-1162
-
-
Marttunen, M.B.1
Hietanen, P.2
Tiitinen, A.3
Ylikorkala, O.4
-
185
-
-
0031962302
-
Tamoxifen and tamoxifene in breast cancer: Comparison of safety and efficacy
-
Buzdar AU, Hortobagyi GN: Tamoxifen and tamoxifene in breast cancer: comparison of safety and efficacy. J Clin Oncol 16: 348-353, 1998
-
(1998)
J Clin Oncol
, vol.16
, pp. 348-353
-
-
Buzdar, A.U.1
Hortobagyi, G.N.2
-
187
-
-
0028068906
-
Droloxifene, a new antiestrogen: Its role in metastatic breast cancer
-
Rauschning W, Pritchard KI: Droloxifene, a new antiestrogen: Its role in metastatic breast cancer. Breast Cancer Res Treat 31: 83-94, 1994
-
(1994)
Breast Cancer Res Treat
, vol.31
, pp. 83-94
-
-
Rauschning, W.1
Pritchard, K.I.2
-
188
-
-
0026345105
-
Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer
-
Chander SK, McCague R, Luqmani Y, Newton C, Dowsett M, Jarman M, Coombes RC: Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer. Cancer Res 51: 5851-5858, 1991
-
(1991)
Cancer Res
, vol.51
, pp. 5851-5858
-
-
Chander, S.K.1
McCague, R.2
Luqmani, Y.3
Newton, C.4
Dowsett, M.5
Jarman, M.6
Coombes, R.C.7
-
189
-
-
0030750807
-
Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts
-
Pace P, Jarman M, Phillips D, Hewer A, Bliss J, Coombes RC: Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts. Br J Cancer 76: 700-704, 1997
-
(1997)
Br J Cancer
, vol.76
, pp. 700-704
-
-
Pace, P.1
Jarman, M.2
Phillips, D.3
Hewer, A.4
Bliss, J.5
Coombes, R.C.6
-
190
-
-
0031039798
-
The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance
-
Johnston SRD, Riddler S, Haynes BP, A'Hern R, Smith IE, Jarman M, Dowsett M: The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance. Br J Cancer 75: 804-809, 1997
-
(1997)
Br J Cancer
, vol.75
, pp. 804-809
-
-
Johnston, S.R.D.1
Riddler, S.2
Haynes, B.P.3
A'Hern, R.4
Smith, I.E.5
Jarman, M.6
Dowsett, M.7
-
191
-
-
0028935148
-
Idoxifene: Report of a phase I study in patients with metastatic breast cancer
-
Coombes RC, Haynes BP, Dowsett M, Quigley M, English J, Judson IR, Griggs LJ, Potter GA, McCague R, Jarman M: Idoxifene: Report of a phase I study in patients with metastatic breast cancer. Cancer Res 55: 1070-1074, 1995
-
(1995)
Cancer Res
, vol.55
, pp. 1070-1074
-
-
Coombes, R.C.1
Haynes, B.P.2
Dowsett, M.3
Quigley, M.4
English, J.5
Judson, I.R.6
Griggs, L.J.7
Potter, G.A.8
McCague, R.9
Jarman, M.10
-
192
-
-
0027279120
-
MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780
-
Brünner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME, Clarke R: MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res 53: 3229-3232, 1993
-
(1993)
Cancer Res
, vol.53
, pp. 3229-3232
-
-
Brünner, N.1
Frandsen, T.L.2
Holst-Hansen, C.3
Bei, M.4
Thompson, E.W.5
Wakeling, A.E.6
Lippman, M.E.7
Clarke, R.8
-
193
-
-
0024319781
-
Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens
-
Gottardis MM, Jiang SY, Jeng MH, Jordan VC: Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49: 4090-4093, 1989
-
(1989)
Cancer Res
, vol.49
, pp. 4090-4093
-
-
Gottardis, M.M.1
Jiang, S.Y.2
Jeng, M.H.3
Jordan, V.C.4
-
194
-
-
0029075872
-
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer
-
Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI: Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87: 746-750, 1995
-
(1995)
J Natl Cancer Inst
, vol.87
, pp. 746-750
-
-
Osborne, C.K.1
Coronado-Heinsohn, E.B.2
Hilsenbeck, S.G.3
McCue, B.L.4
Wakeling, A.E.5
McClelland, R.A.6
Manning, D.L.7
Nicholson, R.I.8
-
195
-
-
0032912182
-
Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells
-
Salerno M, Sisci D, Mauro L, Guvakova MA, Ando S, Surmacz E: Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells. Int J Cancer 81: 299-304, 1999
-
(1999)
Int J Cancer
, vol.81
, pp. 299-304
-
-
Salerno, M.1
Sisci, D.2
Mauro, L.3
Guvakova, M.A.4
Ando, S.5
Surmacz, E.6
-
196
-
-
0030016280
-
Pharmacokinetics, pharmacological and anti-tumour effects of the specific antioestrogen ICI 182780 in women with advanced breast cancer
-
Howell A, DeFriend DJ, Robertson JFR, Blamey RW, Anderson L, Anderson E, Sutcliffe FA, Walton P: Pharmacokinetics, pharmacological and anti-tumour effects of the specific antioestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 74: 300-308, 1996
-
(1996)
Br J Cancer
, vol.74
, pp. 300-308
-
-
Howell, A.1
DeFriend, D.J.2
Robertson, J.F.R.3
Blamey, R.W.4
Anderson, L.5
Anderson, E.6
Sutcliffe, F.A.7
Walton, P.8
-
197
-
-
0031730275
-
Effect of the high-affinity estrogen receptor ligand ICI 182,780 on the rat tibia
-
Sibonga JD, Dobnig H, Harden RM, Turner RT: Effect of the high-affinity estrogen receptor ligand ICI 182,780 on the rat tibia. Endocrinology 139: 3736-3742, 1998
-
(1998)
Endocrinology
, vol.139
, pp. 3736-3742
-
-
Sibonga, J.D.1
Dobnig, H.2
Harden, R.M.3
Turner, R.T.4
-
198
-
-
0020582094
-
Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels
-
Clemens JA, Bennett DR, Black LJ, Jones CD: Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci 32: 2875, 1983
-
(1983)
Life Sci
, vol.32
, pp. 2875
-
-
Clemens, J.A.1
Bennett, D.R.2
Black, L.J.3
Jones, C.D.4
-
199
-
-
0023683229
-
Phase II evaluation of Ly156758 in metastatic breast cancer
-
Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G: Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 45: 344-345, 1988
-
(1988)
Oncology
, vol.45
, pp. 344-345
-
-
Buzdar, A.U.1
Marcus, C.2
Holmes, F.3
Hug, V.4
Hortobagyi, G.5
-
200
-
-
0028167482
-
Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats
-
Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU: Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93: 63-69, 1994
-
(1994)
J Clin Invest
, vol.93
, pp. 63-69
-
-
Black, L.J.1
Sato, M.2
Rowley, E.R.3
De Magee4
Bekele, A.5
Williams, D.C.6
Cullinan, G.J.7
Bendele, R.8
Kauffman, R.F.9
Bensch, W.R.10
Frolik, C.A.11
Termine, J.D.12
Bryant, H.U.13
-
201
-
-
0030664688
-
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
-
Delmas PD, Bjarnson NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337: 1641-1647, 1997
-
(1997)
N Engl J Med
, vol.337
, pp. 1641-1647
-
-
Delmas, P.D.1
Bjarnson, N.H.2
Mitlak, B.H.3
Ravoux, A.C.4
Shah, A.S.5
Huster, W.J.6
Draper, M.7
Christiansen, C.8
-
202
-
-
0033575083
-
The effect of raloxifene on risk of breast cancer in postmenopausal women - Results from the MORE trial
-
Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC: The effect of raloxifene on risk of breast cancer in postmenopausal women - Results from the MORE trial. JAMA 281: 2189-2197, 1999
-
(1999)
JAMA
, vol.281
, pp. 2189-2197
-
-
Cummings, S.R.1
Eckert, S.2
Krueger, K.A.3
Grady, D.4
Powles, T.J.5
Cauley, J.A.6
Norton, L.7
Nickelsen, T.8
Bjarnason, N.H.9
Morrow, M.10
Lippman, M.E.11
Black, D.12
Glusman, J.E.13
Costa, A.14
Jordan, V.C.15
-
203
-
-
0002258194
-
Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women. Two year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial
-
Abstract
-
Cummings SR, Norton L, Eckert S, Grady D, Cauley J, Knickerbocker R, Black DM, Nickelsen T, Glusman J, Krueger K: Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women. Two year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. Proc Am Soc Clin Oncol 17: 2a(Abstract), 1998
-
(1998)
Proc am Soc Clin Oncol
, vol.17
-
-
Cummings, S.R.1
Norton, L.2
Eckert, S.3
Grady, D.4
Cauley, J.5
Knickerbocker, R.6
Black, D.M.7
Nickelsen, T.8
Glusman, J.9
Krueger, K.10
-
204
-
-
0032462194
-
LY353381.HC1: A novel raloxifene analog with improved SERM potency and efficacy in vivo
-
Sato M, Turner CH, Wang TY, Adrian MD, Rowley E, Bryant HU: LY353381.HC1: A novel raloxifene analog with improved SERM potency and efficacy in vivo. J Pharmacol Exp Therapeutics 287: 1-7, 1998
-
(1998)
J Pharmacol Exp Therapeutics
, vol.287
, pp. 1-7
-
-
Sato, M.1
Turner, C.H.2
Wang, T.Y.3
Adrian, M.D.4
Rowley, E.5
Bryant, H.U.6
-
205
-
-
0342313112
-
LY353381.HCl, a new benzothiophene for chemoprevention of breast cancer
-
Sporn M, Suh N, Peer C, Williams C, Roebuck B, Glasebrook A, Palkowitz A, Bryant M, Sato M, Yang N, Fuchs-Young R: LY353381.HCl, a new benzothiophene for chemoprevention of breast cancer (Abstract). Proc Am Assoc Cancer Res 38: 3538, 1997
-
(1997)
Proc am Assoc Cancer Res
, vol.38
, pp. 3538
-
-
Sporn, M.1
Suh, N.2
Peer, C.3
Williams, C.4
Roebuck, B.5
Glasebrook, A.6
Palkowitz, A.7
Bryant, M.8
Sato, M.9
Yang, N.10
Fuchs-Young, R.11
-
206
-
-
0031813087
-
Prevention of development of dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH57050)
-
Luo SQ, Labrie C, Belanger A, Candas B, Labrie F: Prevention of development of dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH57050). Breast Cancer Res Treat 49: 1-11, 1998
-
(1998)
Breast Cancer Res Treat
, vol.49
, pp. 1-11
-
-
Luo, S.Q.1
Labrie, C.2
Belanger, A.3
Candas, B.4
Labrie, F.5
-
207
-
-
0030879732
-
Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro
-
Simard J, Labrie C, Belanger A, Gauthier S, Singh SM, Merand Y, Labrie F: Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int J Cancer 73: 104-112, 1997
-
(1997)
Int J Cancer
, vol.73
, pp. 104-112
-
-
Simard, J.1
Labrie, C.2
Belanger, A.3
Gauthier, S.4
Singh, S.M.5
Merand, Y.6
Labrie, F.7
-
208
-
-
0031964105
-
Comparison of the effects of the antiestrogens EM-800 and tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice
-
Couillard S, Gutman M, Labrie C, Belanger A, Candas B, Labrie F: Comparison of the effects of the antiestrogens EM-800 and tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice. Cancer Res 58: 60-64, 1998
-
(1998)
Cancer Res
, vol.58
, pp. 60-64
-
-
Couillard, S.1
Gutman, M.2
Labrie, C.3
Belanger, A.4
Candas, B.5
Labrie, F.6
-
209
-
-
0030711496
-
Morphological changes induced by 6-month treatment of intact and ovariectomized mice with tamoxifen and the pure antiestrogen EM-800
-
Sourla A, Luo S, Labrie C, Belanger A, Labrie F: Morphological changes induced by 6-month treatment of intact and ovariectomized mice with tamoxifen and the pure antiestrogen EM-800. Endocrinology 138: 5605-5617, 1997
-
(1997)
Endocrinology
, vol.138
, pp. 5605-5617
-
-
Sourla, A.1
Luo, S.2
Labrie, C.3
Belanger, A.4
Labrie, F.5
-
210
-
-
0030723512
-
Comparative effects of 28-day treatment with the new anti-estrogen EM-800 and tamoxifen on estrogen-sensitive parameters in intact mice
-
Luo S, Martel C, Sourla A, Gauthier S, Merand Y, Belanger A, Labrie C, Labrie F: Comparative effects of 28-day treatment with the new anti-estrogen EM-800 and tamoxifen on estrogen-sensitive parameters in intact mice. Int J Cancer 73: 381-391, 1997
-
(1997)
Int J Cancer
, vol.73
, pp. 381-391
-
-
Luo, S.1
Martel, C.2
Sourla, A.3
Gauthier, S.4
Merand, Y.5
Belanger, A.6
Labrie, C.7
Labrie, F.8
-
211
-
-
85011457699
-
EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors a and b
-
Tremblay A, Tremblay GB, Labrie C, Labrie F, Giguere V: EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors a and b. Endocrinology 139: 111-118, 1998
-
(1998)
Endocrinology
, vol.139
, pp. 111-118
-
-
Tremblay, A.1
Tremblay, G.B.2
Labrie, C.3
Labrie, F.4
Giguere, V.5
-
212
-
-
0032581614
-
Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene
-
Rosati RL, Jardine PD, Cameron KO, Thompson DD, Ke HZ, Toler SM, Brown TA, Pan LC, Ebbinghaus CF, Reinhold AR, Elliott NC, Newhouse BN, Tjoa CM, Sweetnam PM, Cole MJ, Arriola MW, Gauthier JW, Crawford DT, Nickerson DF, Pirie CM, Qi H, Simmons HA, Tkalcevic GT: Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem 41: 2928-2931, 1998
-
(1998)
J Med Chem
, vol.41
, pp. 2928-2931
-
-
Rosati, R.L.1
Jardine, P.D.2
Cameron, K.O.3
Thompson, D.D.4
Ke, H.Z.5
Toler, S.M.6
Brown, T.A.7
Pan, L.C.8
Ebbinghaus, C.F.9
Reinhold, A.R.10
Elliott, N.C.11
Newhouse, B.N.12
Tjoa, C.M.13
Sweetnam, P.M.14
Cole, M.J.15
Arriola, M.W.16
Gauthier, J.W.17
Crawford, D.T.18
Nickerson, D.F.19
Pirie, C.M.20
Qi, H.21
Simmons, H.A.22
Tkalcevic, G.T.23
more..
-
213
-
-
0001236520
-
Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus, and body composition in rat models
-
Ke HZ, Paralkar VM, Grasser WA, Crawford DT, Qi H, Simmons HA, Pirie CM, Chidsey-Frink KL, Owen TA, Smock SL, Chen HK, Jee WSS, Cameron KO, Rosati RL, Brown TA, Thompson DD: Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus, and body composition in rat models. Endocrinology 139: 2068-2076, 1998
-
(1998)
Endocrinology
, vol.139
, pp. 2068-2076
-
-
Ke, H.Z.1
Paralkar, V.M.2
Grasser, W.A.3
Crawford, D.T.4
Qi, H.5
Simmons, H.A.6
Pirie, C.M.7
Chidsey-Frink, K.L.8
Owen, T.A.9
Smock, S.L.10
Chen, H.K.11
Wss, J.12
Cameron, K.O.13
Rosati, R.L.14
Brown, T.A.15
Thompson, D.D.16
-
214
-
-
0029799612
-
Endometrial carcinoma
-
Rose PG: Endometrial carcinoma. N Engl J Med 335: 640-649, 1996
-
(1996)
N Engl J Med
, vol.335
, pp. 640-649
-
-
Rose, P.G.1
-
216
-
-
0030671159
-
Tamoxifen in the treatment of recurrent ovarian cancer
-
Marth C, Sorheim N, Kaern J, Trope C: Tamoxifen in the treatment of recurrent ovarian cancer. Int J Gynecol Cancer 7: 256-261, 1997
-
(1997)
Int J Gynecol Cancer
, vol.7
, pp. 256-261
-
-
Marth, C.1
Sorheim, N.2
Kaern, J.3
Trope, C.4
-
217
-
-
0026588138
-
Hormone receptors in malignancy
-
Danforth DN, Jr.: Hormone receptors in malignancy. Crit Rev Oncol Hematol 12: 91-149, 1992
-
(1992)
Crit Rev Oncol Hematol
, vol.12
, pp. 91-149
-
-
Danforth D.N., Jr.1
-
218
-
-
0031928243
-
Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1)
-
Rohlff C, Blagosklonny MV, Kyle E, Kesari A, Kim IY, Zelner DJ, Hakim F, Trepel J, Bergan RC: Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1). Prostate 37: 51-59, 1998
-
(1998)
Prostate
, vol.37
, pp. 51-59
-
-
Rohlff, C.1
Blagosklonny, M.V.2
Kyle, E.3
Kesari, A.4
Kim, I.Y.5
Zelner, D.J.6
Hakim, F.7
Trepel, J.8
Bergan, R.C.9
-
219
-
-
0032170090
-
Antiestrogens induce apoptosis of multiple myeloma cells
-
Treon SP, Teoh G, Urashima M, Ogata A, Chauhan D, Webb IJ, Anderson KC: Antiestrogens induce apoptosis of multiple myeloma cells. Blood 92: 1749-1757, 1998
-
(1998)
Blood
, vol.92
, pp. 1749-1757
-
-
Treon, S.P.1
Teoh, G.2
Urashima, M.3
Ogata, A.4
Chauhan, D.5
Webb, I.J.6
Anderson, K.C.7
-
220
-
-
0030941284
-
Tamoxifen-mediated growth inhibition of human cholangiocarcinoma
-
Sampson LK, Vickers SM, Ying WZ, Phillips JO: Tamoxifen-mediated growth inhibition of human cholangiocarcinoma. Cancer Res 57: 1743-1749, 1997
-
(1997)
Cancer Res
, vol.57
, pp. 1743-1749
-
-
Sampson, L.K.1
Vickers, S.M.2
Ying, W.Z.3
Phillips, J.O.4
-
221
-
-
0031034831
-
High dose toremifene in advanced renal-cell carcinoma
-
Gershanovich MM, Moiseyenko VM, Vorobjev AV, Kapyla H, Ellmen J, Anttila M: High dose toremifene in advanced renal-cell carcinoma. Cancer Chemother Pharmacol 39: 547-551, 1997
-
(1997)
Cancer Chemother Pharmacol
, vol.39
, pp. 547-551
-
-
Gershanovich, M.M.1
Moiseyenko, V.M.2
Vorobjev, A.V.3
Kapyla, H.4
Ellmen, J.5
Anttila, M.6
-
222
-
-
0031052651
-
Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma
-
Gelmann EP: Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin Oncol 24: S65-S70, 1997
-
(1997)
Semin Oncol
, vol.24
-
-
Gelmann, E.P.1
-
223
-
-
0029999729
-
Regression of large pelvic desmoid tumor by tamoxifen and sulindac
-
Izes JK, Zinman LN, Larsen CR: Regression of large pelvic desmoid tumor by tamoxifen and sulindac. Urology 47: 756-759, 1996
-
(1996)
Urology
, vol.47
, pp. 756-759
-
-
Izes, J.K.1
Zinman, L.N.2
Larsen, C.R.3
-
224
-
-
0031047959
-
Treatment of idiopathic retroperitoneal fibrosis by tamoxifen
-
Tonietto G, Agresta F, Libera DD, Bittesini L: Treatment of idiopathic retroperitoneal fibrosis by tamoxifen. Eur J Surg 163: 231-235, 1997
-
(1997)
Eur J Surg
, vol.163
, pp. 231-235
-
-
Tonietto, G.1
Agresta, F.2
Libera, D.D.3
Bittesini, L.4
-
225
-
-
0030593681
-
ERb: Identification and characterization of a novel human estrogen receptor
-
Mosselman S, Polman J, Dijkema R: ERb: Identification and characterization of a novel human estrogen receptor. FEBS Lett 392: 49-53, 1996
-
(1996)
FEBS Lett
, vol.392
, pp. 49-53
-
-
Mosselman, S.1
Polman, J.2
Dijkema, R.3
-
226
-
-
0030733906
-
Human estrogen receptor b-gene structure, chromosomal localization, and expression pattern
-
Enmark E, PeltoHuikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjold M, Gustafsson JA: Human estrogen receptor b-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 82: 4258-4265, 1997
-
(1997)
J Clin Endocrinol Metab
, vol.82
, pp. 4258-4265
-
-
Enmark, E.1
PeltoHuikko, M.2
Grandien, K.3
Lagercrantz, S.4
Lagercrantz, J.5
Fried, G.6
Nordenskjold, M.7
Gustafsson, J.A.8
-
227
-
-
0032481256
-
The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro
-
Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, Ouchi Y, Muramatsu M: The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem Biophys Res Commun 243: 122-126, 1998
-
(1998)
Biochem Biophys Res Commun
, vol.243
, pp. 122-126
-
-
Ogawa, S.1
Inoue, S.2
Watanabe, T.3
Hiroi, H.4
Orimo, A.5
Hosoi, T.6
Ouchi, Y.7
Muramatsu, M.8
-
228
-
-
0030747070
-
Mwse estrogen receptor b forms estrogen response element-binding heterodimers with estrogen receptor a
-
Pettersson K, Grandien K, Kuiper GGJM, Gustafsson JA: Mwse estrogen receptor b forms estrogen response element-binding heterodimers with estrogen receptor a. Mol Endocrinol 11: 1486-1496, 1997
-
(1997)
Mol Endocrinol
, vol.11
, pp. 1486-1496
-
-
Pettersson, K.1
Grandien, K.2
Kuiper, G.G.J.M.3
Gustafsson, J.A.4
-
229
-
-
0030738318
-
The novel estrogen receptor-b subtype: Potential role in the cell- And promoter-specific actions of estrogens and anti-estrogens
-
Kuiper GGJM, Gustafsson JA: The novel estrogen receptor-b subtype: Potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett 410: 87-90, 1997
-
(1997)
FEBS Lett
, vol.410
, pp. 87-90
-
-
Kuiper, G.G.J.M.1
Gustafsson, J.A.2
-
230
-
-
0030752456
-
Estrogen receptors a and b form heterodimers on DNA
-
Cowley SM, Hoare S, Mosselman S, Parker MG: Estrogen receptors a and b form heterodimers on DNA. J Biol Chem 272: 19858-19862, 1997
-
(1997)
J Biol Chem
, vol.272
, pp. 19858-19862
-
-
Cowley, S.M.1
Hoare, S.2
Mosselman, S.3
Parker, M.G.4
-
231
-
-
0031816540
-
Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonist-slantagonists
-
Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson JA, Nilsson S: Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonist-slantagonists. Mol Pharnacol 54: 105-112, 1998
-
(1998)
Mol Pharnacol
, vol.54
, pp. 105-112
-
-
Barkhem, T.1
Carlsson, B.2
Nilsson, Y.3
Enmark, E.4
Gustafsson, J.A.5
Nilsson, S.6
-
232
-
-
0030801841
-
Differential activation of estrogen receptors ERa and ERb at API sites
-
Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson JA, Kushner PJ, Scanlan TS: Differential activation of estrogen receptors ERa and ERb at API sites. Science 277: 1508-1510, 1997
-
(1997)
Science
, vol.277
, pp. 1508-1510
-
-
Paech, K.1
Webb, P.2
Kuiper, G.G.J.M.3
Nilsson, S.4
Gustafsson, J.A.5
Kushner, P.J.6
Scanlan, T.S.7
-
233
-
-
0030744629
-
Expression of estrogen receptor-beta in human breast tumors
-
Dotzlaw H, Leygue E, Watson PH, Murphy LC: Expression of estrogen receptor-beta in human breast tumors. J Clin Endocrinol Metab 82: 2371-2374, 1997
-
(1997)
J Clin Endocrinol Metab
, vol.82
, pp. 2371-2374
-
-
Dotzlaw, H.1
Leygue, E.2
Watson, P.H.3
Murphy, L.C.4
-
234
-
-
0033083821
-
Estrogen receptor-beta messenger RNA expression in human breast tumor biopsies: Relationship to steroid receptor status and regulation by progestins
-
Dotzlaw H, Leygue E, Watson PH, Murphy LC: Estrogen receptor-beta messenger RNA expression in human breast tumor biopsies: Relationship to steroid receptor status and regulation by progestins. Cancer Res 59: 529-532, 1999
-
(1999)
Cancer Res
, vol.59
, pp. 529-532
-
-
Dotzlaw, H.1
Leygue, E.2
Watson, P.H.3
Murphy, L.C.4
-
235
-
-
0031791153
-
Identification of estrogen receptor b2, a functional variant of estrogen receptor b expressed in normal rat tissues
-
Petersen DN, Tkalcevic GT, Koza-Taylor PH, Turi TG, Brown TA: Identification of estrogen receptor b2, a functional variant of estrogen receptor b expressed in normal rat tissues. Endocrinology 139: 1082-1092, 1998
-
(1998)
Endocrinology
, vol.139
, pp. 1082-1092
-
-
Petersen, D.N.1
Tkalcevic, G.T.2
Koza-Taylor, P.H.3
Turi, T.G.4
Brown, T.A.5
-
236
-
-
0033559575
-
Expression of estrogen receptor beta 1, beta 2, and beta 5 messenger RNAs in human breast tissue
-
Leygue E, Dotzlaw H, Watson PH, Murphy LC: Expression of estrogen receptor beta 1, beta 2, and beta 5 messenger RNAs in human breast tissue. Cancer Res 59: 1175-1179, 1999
-
(1999)
Cancer Res
, vol.59
, pp. 1175-1179
-
-
Leygue, E.1
Dotzlaw, H.2
Watson, P.H.3
Murphy, L.C.4
-
237
-
-
0023573087
-
Interaction of retinoids and tamoxifen on the inhibition of human mammary carcinoma ceil proliferation
-
Fontana JA: Interaction of retinoids and tamoxifen on the inhibition of human mammary carcinoma ceil proliferation. Exp Cell Biol 55: 136-144, 1987
-
(1987)
Exp Cell Biol
, vol.55
, pp. 136-144
-
-
Fontana, J.A.1
-
238
-
-
0024321412
-
Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats
-
Ratko TA, Detrisac CJ, Dinger NM, Thomas CF, Kelloff GJ, Moon RC: Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res 49: 4472-4476, 1989
-
(1989)
Cancer Res
, vol.49
, pp. 4472-4476
-
-
Ratko, T.A.1
Detrisac, C.J.2
Dinger, N.M.3
Thomas, C.F.4
Kelloff, G.J.5
Moon, R.C.6
-
239
-
-
0032006028
-
Beyond tamoxifen: The retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma
-
Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW: Beyond tamoxifen: The retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res 58: 479-484, 1998
-
(1998)
Cancer Res
, vol.58
, pp. 479-484
-
-
Bischoff, E.D.1
Gottardis, M.M.2
Moon, T.E.3
Heyman, R.A.4
Lamph, W.W.5
-
240
-
-
13344259303
-
Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid
-
Anzano MA, Peer CW, Smith JM, Mullen LT, Shrader MW, Logsdon DL, Driver CL, Brown CC, Roberts AB, Sporn MB: Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst 88: 123-125, 1996
-
(1996)
J Natl Cancer Inst
, vol.88
, pp. 123-125
-
-
Anzano, M.A.1
Peer, C.W.2
Smith, J.M.3
Mullen, L.T.4
Shrader, M.W.5
Logsdon, D.L.6
Driver, C.L.7
Brown, C.C.8
Roberts, A.B.9
Sporn, M.B.10
-
241
-
-
0030812967
-
Synthesis and structure-activity relationships of potent retinoid X receptor ligands
-
Farmer LJ, Jeong S, Kallel EA, Koch SSC, Croston GE, Flatten KS, Heyman RA, Nadzan AM: Synthesis and structure-activity relationships of potent retinoid X receptor ligands. Bioorg Med Chem 7: 2393-2398, 1997
-
(1997)
Bioorg Med Chem
, vol.7
, pp. 2393-2398
-
-
Farmer, L.J.1
Jeong, S.2
Kallel, E.A.3
Koch, S.S.C.4
Croston, G.E.5
Flatten, K.S.6
Heyman, R.A.7
Nadzan, A.M.8
-
242
-
-
0031838157
-
Induction of apoptosis in MCF-7 breast carcinoma cell line by RAR and RXR selective retinoids
-
Toma S, Isnardi L, Riccardi L, Bollag W: Induction of apoptosis in MCF-7 breast carcinoma cell line by RAR and RXR selective retinoids. Anticancer Res 18: 935-942, 1998
-
(1998)
Anticancer Res
, vol.18
, pp. 935-942
-
-
Toma, S.1
Isnardi, L.2
Riccardi, L.3
Bollag, W.4
-
243
-
-
0031993322
-
Terminal differentiation of human breast cancer through PPAR gamma
-
Evans RM, Fletcher C, Martin KJ, Mueller E, Sarraf P, Singer S, Spiegelman BM, Tontonoz P, Zhang M: Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1: 465-470, 1998
-
(1998)
Mol Cell
, vol.1
, pp. 465-470
-
-
Evans, R.M.1
Fletcher, C.2
Martin, K.J.3
Mueller, E.4
Sarraf, P.5
Singer, S.6
Spiegelman, B.M.7
Tontonoz, P.8
Zhang, M.9
-
244
-
-
0032555196
-
Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
-
Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP: Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95: 8806-8811, 1998
-
(1998)
Proc Natl Acad Sci USA
, vol.95
, pp. 8806-8811
-
-
Elstner, E.1
Muller, C.2
Koshizuka, K.3
Williamson, E.A.4
Park, D.5
Asou, H.6
Shintaku, P.7
Said, J.W.8
Heber, D.9
Koeffler, H.P.10
-
245
-
-
0027988168
-
Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen
-
Vink-van Wijngaarden T, Pols HAP, Buurman CJ, Van den Bemd GJCM, Dorssers LCJ, Birkenhäger JC, Van Leeuwen JPTM: Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen. Cancer Res 54: 5711-5717, 1994
-
(1994)
Cancer Res
, vol.54
, pp. 5711-5717
-
-
Vink-van Wijngaarden, T.1
Pols, H.A.P.2
Buurman, C.J.3
Van Den Bemd, G.J.C.M.4
Dorssers, L.C.J.5
Birkenhäger, J.C.6
Van Leeuwen, J.P.T.M.7
-
246
-
-
0032146179
-
19-nor-26,27-bishomo-vitamin D-3 analogs: A unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells
-
Kubota T, Koshizuka K, Koike M, Uskokovic M, Miyoshi I, Koeffler NP: 19-nor-26,27-bishomo-vitamin D-3 analogs: A unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells. Cancer Res 58: 3370-3375, 1998
-
(1998)
Cancer Res
, vol.58
, pp. 3370-3375
-
-
Kubota, T.1
Koshizuka, K.2
Koike, M.3
Uskokovic, M.4
Miyoshi, I.5
Koeffler, N.P.6
-
247
-
-
0032230284
-
Estrogen receptor, a common interaction partner for a subset of nuclear receptors
-
Lee SK, Choi HS, Song MR, Lee MO, Lee JW: Estrogen receptor, a common interaction partner for a subset of nuclear receptors. Mol Endocrinol 12: 1184-1192, 1998
-
(1998)
Mol Endocrinol
, vol.12
, pp. 1184-1192
-
-
Lee, S.K.1
Choi, H.S.2
Song, M.R.3
Lee, M.O.4
Lee, J.W.5
|